BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 813] [Article Influence: 67.5] [Reference Citation Analysis]
Number Citing Articles
1 Li L, Yan J, Xu J, Liu CQ, Zhen ZJ, Chen HW, Ji Y, Wu ZP, Hu JY, Zheng L, Lau WY. CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. PLoS One 2014;9:e110064. [PMID: 25303284 DOI: 10.1371/journal.pone.0110064] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
2 Xue ST, Li K, Gao Y, Zhao LY, Gao Y, Yi H, Jiang JD, Li ZR. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target. Autophagy 2020;16:1823-37. [PMID: 31986961 DOI: 10.1080/15548627.2019.1709762] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Yang WX, Pan YY, You CG. CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. Biomed Res Int 2019;2019:1245072. [PMID: 31737652 DOI: 10.1155/2019/1245072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
4 Lv H, Zhang Z, Wu X, Wang Y, Li C, Gong W, Gui L, Wang X. Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent. PLoS One 2016;11:e0145195. [PMID: 26727592 DOI: 10.1371/journal.pone.0145195] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:171-179. [PMID: 23558072 DOI: 10.1016/S1499-3872(13)60028-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
6 Yin LC, Xiao G, Zhou R, Huang XP, Li NL, Tan CL, Xie FJ, Weng J, Liu LX. MicroRNA-361-5p Inhibits Tumorigenesis and the EMT of HCC by Targeting Twist1. Biomed Res Int 2020;2020:8891876. [PMID: 33381597 DOI: 10.1155/2020/8891876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Enokida T, Moreira A, Bhardwaj N. Vaccines for immunoprevention of cancer. J Clin Invest 2021;131:146956. [PMID: 33938446 DOI: 10.1172/JCI146956] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Chou TC, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML. Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. Clin Transl Gastroenterol 2018;9:166. [PMID: 29961754 DOI: 10.1038/s41424-018-0033-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yuan J, Han B, Hu H, Qian Y, Liu Z, Wei Z, Liang X, Jiang B, Shao C, Gong Y. CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists. J Pathol 2015;235:784-95. [PMID: 25430888 DOI: 10.1002/path.4492] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
10 Nahm JH, Rhee H, Kim H, Yoo JE, San Lee J, Jeon Y, Choi GH, Park YN. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study. Oncotarget. 2017;8:99359-99371. [PMID: 29245907 DOI: 10.18632/oncotarget.22078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Zeng X, Wang N, Zhai H, Wang R, Wu J, Pu W. SIRT3 functions as a tumor suppressor in hepatocellular carcinoma. Tumour Biol 2017;39:1010428317691178. [PMID: 28347248 DOI: 10.1177/1010428317691178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Xiao H, Zhang Y, Li Z, Liu B, Cui D, Liu F, Chen D, Liu Y, Ouyang G. Periostin deficiency reduces diethylnitrosamine-induced liver cancer in mice by decreasing hepatic stellate cell activation and cancer cell proliferation. J Pathol 2021. [PMID: 34228359 DOI: 10.1002/path.5756] [Reference Citation Analysis]
13 Deng H, Zhou Z, Tu W, Xia Y, Huang H, Tian D. Knockdown of astrocyte elevated gene-1 inhibits growth through suppression of IL-6 secretion in HepG2 human hepatoma cells. Oncol Lett 2014;7:101-6. [PMID: 24348829 DOI: 10.3892/ol.2013.1645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
14 Dai B, Geng L, Yu Y, Sui C, Xie F, Shen W, Zheng T, Yang J. Methylation patterns of estrogen receptor α promoter correlate with estrogen receptor α expression and clinicopathological factors in hepatocellular carcinoma. Exp Biol Med (Maywood). 2014;239:883-890. [PMID: 24939822 DOI: 10.1177/1535370214536651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
15 Ponziani FR, Annicchiarico EB, Siciliano M, D’Aversa F, Pompili M, Gasbarrini A. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. World J Gastroenterol 2013; 19(21): 3255-3262 [PMID: 23745027 DOI: 10.3748/wjg.v19.i21.3255] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
16 Zhang S, Shi W, Chen Y, Xu Z, Zhu J, Zhang T, Huang W, Ni R, Lu C, Zhang X. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma. Mol Cell Biochem 2015;410:1-9. [PMID: 26260052 DOI: 10.1007/s11010-015-2533-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
17 Dimri M, Satyanarayana A. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E491. [PMID: 32093152 DOI: 10.3390/cancers12020491] [Cited by in F6Publishing: 48] [Reference Citation Analysis]
18 Markowitz GJ, Yang P, Fu J, Michelotti GA, Chen R, Sui J, Yang B, Qin WH, Zhang Z, Wang FS, Diehl AM, Li QJ, Wang H, Wang XF. Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes. Cancer Res 2016;76:2394-405. [PMID: 26893476 DOI: 10.1158/0008-5472.CAN-15-1548] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
19 Zuure FR, Bouman J, Martens M, Vanhommerig JW, Urbanus AT, Davidovich U, van Houdt R, Speksnijder AG, Weegink CJ, van den Hoek A. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. Liver Int. 2013;33:727-738. [PMID: 23448397 DOI: 10.1111/liv.12131] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
20 Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, Miyakawa Y, Nishino H, Tajiri H. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol. 2012;29:2800-2808. [PMID: 22460836 DOI: 10.1007/s12032-012-0220-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
21 Seitz S, Iancu C, Volz T, Mier W, Dandri M, Urban S, Bartenschlager R. A Slow Maturation Process Renders Hepatitis B Virus Infectious. Cell Host Microbe 2016;20:25-35. [PMID: 27321908 DOI: 10.1016/j.chom.2016.05.013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
22 Mohamed EA, Giama NH, Shaleh HM, Kerandi L, Oseini AM, Ahmed Mohammed H, Kerandi H, Allotey LK, Waaeys IA, Ali HA, Ali HM, Mohamed SA, Yang JD, Gaga WO, Tamire LL, Windissa A, Patten CA, Balls-Berry JE, Roberts LR. Knowledge, Attitudes, and Behaviors of Viral Hepatitis Among Recent African Immigrants in the United States: A Community Based Participatory Research Qualitative Study. Front Public Health 2020;8:25. [PMID: 32211358 DOI: 10.3389/fpubh.2020.00025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Liu C, Xu G, Gao Z, Zhou Z, Guo G, Li D, Jing Z, Sui J, Li W. The p.Ser267Phe variant of sodium taurocholate cotransporting polypeptide (NTCP) supports HBV infection with a low efficiency. Virology 2018;522:168-76. [PMID: 30032030 DOI: 10.1016/j.virol.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol 2013;30:673. [PMID: 23912699 DOI: 10.1007/s12032-013-0673-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
26 Yan XD, Yao M, Wang L, Zhang HJ, Yan MJ, Gu X, Shi Y, Chen J, Dong ZZ, Yao DF. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation. World J Gastroenterol 2013; 19(36): 6084-6092 [PMID: 24106410 DOI: 10.3748/wjg.v19.i36.6084] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
27 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
28 Liu B, Fang M, Hu Y, Huang B, Li N, Chang C, Huang R, Xu X, Yang Z, Chen Z, Liu W. Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation. Autophagy. 2014;10:416-430. [PMID: 24401568 DOI: 10.4161/auto.27286] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 10.8] [Reference Citation Analysis]
29 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
30 Costantini C, Bellet MM, Pariano M, Renga G, Stincardini C, Goldstein AL, Garaci E, Romani L. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019;9:873. [PMID: 31555601 DOI: 10.3389/fonc.2019.00873] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
31 Sokolov E, Eheim AL, Ahrens WA, Walling TL, Swet JH, McMillan MT, Simo KA, Thompson KJ, Sindram D, McKillop IH. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma. J Surg Res 2013;180:104-13. [PMID: 23182454 DOI: 10.1016/j.jss.2012.10.054] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
32 Li PY, Yao L, Guo B, Song JW. Interleukin-28B gene polymorphisms: a new beginning of personalized treatment of hepatitis C. Shijie Huaren Xiaohua Zazhi 2012; 20(2): 119-124 [DOI: 10.11569/wcjd.v20.i2.119] [Reference Citation Analysis]
33 Wang Y, Han C, Lu L, Magliato S, Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology. 2013;58:995-1010. [PMID: 23504944 DOI: 10.1002/hep.26394] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 10.9] [Reference Citation Analysis]
34 Jiang B, Zhang R, Zhang J, Hou Y, Chen X, Zhou M, Tian X, Hao C, Fan K, Yan X. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy. Theranostics 2019;9:2167-82. [PMID: 31149036 DOI: 10.7150/thno.30867] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
35 Yang JD, Altekruse SF, Nguyen MH, Gores GJ, Roberts LR. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer. 2017;123:81-89. [PMID: 27571320 DOI: 10.1002/cncr.30246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
36 Choi Y, Oh ST, Won M, Choi KM, Ko MJ, Seo D, Jeon T, Baik IH, Ye S, Park KU, Park I, Jang B, Seo J, Lee Y. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2016;478:1674-81. [DOI: 10.1016/j.bbrc.2016.09.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
37 Hu M, Tong Y, Fang H, Tang J, Liu L, Hu Y, Li J, Zhong L. IL36 indicating good prognosis in human Hepatocellular Carcinoma. J Cancer 2020;11:6248-55. [PMID: 33033508 DOI: 10.7150/jca.47106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Su L, Zhang X, Ma Y, Geng C, Huang X, Hu J, Li T, Tang S, Shen C, Gao Z, Zhang X, Chen JJ. New guaiane-type sesquiterpenoid dimers from Artemisia atrovirens and their antihepatoma activity. Acta Pharm Sin B 2021;11:1648-66. [PMID: 34221874 DOI: 10.1016/j.apsb.2020.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Shan Y, Li P. Long Intergenic Non-Protein Coding RNA 665 Regulates Viability, Apoptosis, and Autophagy via the MiR-186-5p/MAP4K3 Axis in Hepatocellular Carcinoma. Yonsei Med J. 2019;60:842-853. [PMID: 31433582 DOI: 10.3349/ymj.2019.60.9.842] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
40 Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol. 2017;26:138-145. [PMID: 28577719 DOI: 10.1016/j.suronc.2017.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
41 Mizandari M, Azrumelashvili T, Paksashvili N, Kikodze N, Pantsulaia Ia, Janikashvili N, Chikovani T. Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal Ablation. Case Reports Hepatol 2016;2016:6843121. [PMID: 27579192 DOI: 10.1155/2016/6843121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Sarkar D. AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res 2013;120:193-221. [PMID: 23889992 DOI: 10.1016/B978-0-12-401676-7.00007-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
43 Dazert E, Colombi M, Boldanova T, Moes S, Adametz D, Quagliata L, Roth V, Terracciano L, Heim MH, Jenoe P, Hall MN. Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proc Natl Acad Sci U S A 2016;113:1381-6. [PMID: 26787912 DOI: 10.1073/pnas.1523434113] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
44 Brandon-Warner E, Walling TL, Schrum LW, McKillop IH. Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis. Alcohol Clin Exp Res. 2012;36:641-653. [PMID: 22017344 DOI: 10.1111/j.1530-0277.2011.01660.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
45 Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, Larson JJ, Pedersen RA, Therneau TM, Gores GJ. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012;56:614-621. [PMID: 22370914 DOI: 10.1002/hep.25680] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
46 Chen R, Gao Z, Wu X, Campbell JL, Zhang P, Chen B. Hepatocellular carcinoma presenting as thoracic spinal canal metastasis with no clinical primary foci: A report of a rare case and review of the literature. Oncol Lett 2015;10:2333-6. [PMID: 26622846 DOI: 10.3892/ol.2015.3569] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
47 Pilapong C, Sitthichai S, Thongtem S, Thongtem T. Smart magnetic nanoparticle-aptamer probe for targeted imaging and treatment of hepatocellular carcinoma. Int J Pharm. 2014;473:469-474. [PMID: 25089503 DOI: 10.1016/j.ijpharm.2014.07.036] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
48 Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R, Chen Y, Gao X, Zhu Q, Yue X, Pan Q, Xu S, Li J, Huang M, Daugherty-Holtrop J, He Y, Xu HE, Fan J, Ding J, Geng M. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst 2011;103:1696-712. [PMID: 22025622 DOI: 10.1093/jnci/djr360] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
49 Shao D, Li J, Zheng X, Pan Y, Wang Z, Zhang M, Chen Q, Dong W, Chen L. Janus “nano-bullets” for magnetic targeting liver cancer chemotherapy. Biomaterials 2016;100:118-33. [DOI: 10.1016/j.biomaterials.2016.05.030] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 14.5] [Reference Citation Analysis]
50 Wu ZF, Xu Z, Li WS, Zhang HB, Yang N, Yao XQ, Liu FK, Yang GS. Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res 2015;193:153-60. [PMID: 25128925 DOI: 10.1016/j.jss.2014.07.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
51 Li Y, Yang Y, Li Y, Zhang P, Ge G, Jin J, Du T, Ma M, Na L, Ding L, Sheng H. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis. J Int Med Res 2021;49:3000605211055378. [PMID: 34772312 DOI: 10.1177/03000605211055378] [Reference Citation Analysis]
52 Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y. Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021;11:733595. [PMID: 34527595 DOI: 10.3389/fonc.2021.733595] [Reference Citation Analysis]
53 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Lu P, Ding Q, Ding S, Fan Y, Li X, Tian D, Liu M. Transmembrane channel-like protein 8 as a potential biomarker for poor prognosis of hepatocellular carcinoma. Mol Clin Oncol 2017;7:244-8. [PMID: 28781795 DOI: 10.3892/mco.2017.1285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Liu N, Chang CW, Steer CJ, Wang XW, Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology 2021:S0016-5085(21)03652-0. [PMID: 34678217 DOI: 10.1053/j.gastro.2021.10.015] [Reference Citation Analysis]
56 Wang P, Sheng L, Wang G, Wang H, Huang X, Yan X, Yang X, Pei R. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. Mol Clin Oncol 2014;2:203-6. [PMID: 24649333 DOI: 10.3892/mco.2014.239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
57 Sinn DH, Gwak GY, Cho J, Paik SW, Yoo BC. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One. 2014;9:e112184. [PMID: 25372403 DOI: 10.1371/journal.pone.0112184] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
58 Li Z, Huang X, Zhan H, Zeng Z, Li C, Spitsbergen JM, Meierjohann S, Schartl M, Gong Z. Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish. J Hepatol. 2012;56:419-425. [PMID: 21888874 DOI: 10.1016/j.jhep.2011.07.025] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 7.3] [Reference Citation Analysis]
59 Müller-coan BG, Caetano BFR, Pagano JS, Elgui de Oliveira D. Cancer Progression Goes Viral: The Role of Oncoviruses in Aggressiveness of Malignancies. Trends in Cancer 2018;4:485-98. [DOI: 10.1016/j.trecan.2018.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 Wang Y, Jiang J, Ma H, Han J, Sun Z, Liu Z, Xu Z. Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. Tumor Biol 2014;35:7429-33. [DOI: 10.1007/s13277-014-1971-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
61 Chen M, Luo F, Yu J, Xiang G, Jiang D, Pu X. Common functional polymorphism within miR-146a and miR-196a-2 as susceptibility loci for hepatocellular carcinoma: An updated meta-analysis. Meta Gene 2016;7:40-7. [PMID: 26862480 DOI: 10.1016/j.mgene.2015.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
62 Guo L, Ren H, Pu L, Zhu X, Liu Y, Ma X. The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study. Cancer Manag Res 2020;12:7173-88. [PMID: 33061563 DOI: 10.2147/CMAR.S257934] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Kawaguchi K, Honda M, Yamashita T, Okada H, Shirasaki T, Nishikawa M, Nio K, Arai K, Sakai Y, Yamashita T. Jagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer. Am J Pathol. 2016;186:2055-2067. [PMID: 27315779 DOI: 10.1016/j.ajpath.2016.04.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
64 Yan S, Xu D, Sun B. Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis. Dig Dis Sci 2013;58:2107-13. [DOI: 10.1007/s10620-013-2570-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
65 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 76] [Article Influence: 19.4] [Reference Citation Analysis]
66 Cano L, Cerapio JP, Ruiz E, Marchio A, Turlin B, Casavilca S, Taxa L, Marti G, Deharo E, Pineau P, Bertani S. Liver clear cell foci and viral infection are associated with non-cirrhotic, non-fibrolamellar hepatocellular carcinoma in young patients from South America. Sci Rep 2018;8:9945. [PMID: 30061721 DOI: 10.1038/s41598-018-28286-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Baldissera V, Alves A, Almeida S, Porawski M, Giovenardi M. Hepatocellular carcinoma and estrogen receptors: Polymorphisms and isoforms relations and implications. Medical Hypotheses 2016;86:67-70. [DOI: 10.1016/j.mehy.2015.11.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
68 Ezzat WM, Amr KS. Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention. World J Hepatol 2016;8:1251-61. [PMID: 27843535 DOI: 10.4254/wjh.v8.i30.1251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
69 Dai Q, Deng J, Zhou J, Wang Z, Yuan XF, Pan S, Zhang HB. Long non-coding RNA TUG1 promotes cell progression in hepatocellular carcinoma via regulating miR-216b-5p/DLX2 axis. Cancer Cell Int. 2020;20:8. [PMID: 31920462 DOI: 10.1186/s12935-019-1093-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
70 Li YC, Yang CS, Zhou WL, Li HS, Han YJ, Wang QS, Wu HB. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. World J Gastroenterol 2018; 24(4): 494-503 [PMID: 29398870 DOI: 10.3748/wjg.v24.i4.494] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
71 Lasher CD, Rajagopalan P, Murali TM. Summarizing cellular responses as biological process networks. BMC Syst Biol 2013;7:68. [PMID: 23895181 DOI: 10.1186/1752-0509-7-68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy. 2015;26:911-921. [PMID: 26298331 DOI: 10.1016/j.drugpo.2015.07.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
73 Xing QT, Qu CM, Wang G. Overexpression of Abl2 predicts poor prognosis in hepatocellular carcinomas and is associated with cancer cell migration and invasion. Onco Targets Ther 2014;7:881-5. [PMID: 24940071 DOI: 10.2147/OTT.S62348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
74 Zhang JP, Wang HB, Lin YH, Xu J, Wang J, Wang K, Liu WL. Lactate Dehydrogenase Is an Important Prognostic Indicator for Hepatocellular Carcinoma after Partial Hepatectomy. Transl Oncol 2015;8:497-503. [PMID: 26692531 DOI: 10.1016/j.tranon.2015.11.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
75 Chang MS, Nguyen MH. Epidemiology of hepatitis B and the role of vaccination. Best Pract Res Clin Gastroenterol 2017;31:239-47. [PMID: 28774405 DOI: 10.1016/j.bpg.2017.05.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
76 Lori JR, McCullagh MC, Krueger A, Oteng R. Sharps injuries among emergency department nurses in one tertiary care hospital in Ghana. Int Emerg Nurs 2016;28:14-9. [PMID: 26796286 DOI: 10.1016/j.ienj.2015.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
77 Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, Kreipe H, Lehmann U. Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS One. 2012;7:e49462. [PMID: 23145177 DOI: 10.1371/journal.pone.0049462] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 9.0] [Reference Citation Analysis]
78 Sun W, Huang H, He B, Hu D, Li P, Yu Y, Zhou X, Lv Z, Zhou L, Hu T, Yao Z, Lu M, Shen X, Zheng Z. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochemical Pharmacology 2017;127:90-100. [DOI: 10.1016/j.bcp.2016.12.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
79 Zigmond E, Ben Ya'acov A, Lee H, Lichtenstein Y, Shalev Z, Smith Y, Zolotarov L, Ziv E, Kalman R, Le HV, Lu H, Silverman RB, Ilan Y. Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase. ACS Med Chem Lett 2015;6:840-4. [PMID: 26288681 DOI: 10.1021/acsmedchemlett.5b00153] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
80 Liao Z, Chen L, Zhang X, Zhang H, Tan X, Dong K, Lu X, Zhu H, Liu Q, Zhang Z, Ding Z, Dong W, Zhu P, Chu L, Liang H, Datta PK, Zhang B, Chen X. PTPRε Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF-β Receptor 1. Hepatology 2020;72:997-1012. [PMID: 31903610 DOI: 10.1002/hep.31104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
81 Wu D, Xia A, Fan T, Li G. circRASGRF2 functions as an oncogenic gene in hepatocellular carcinoma by acting as a miR-1224 sponge. Mol Ther Nucleic Acids 2021;23:13-26. [PMID: 33312757 DOI: 10.1016/j.omtn.2020.10.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
82 Rauff B, Douglas MW. Role of fibrogenic and inflammatory cytokines in HCV-induced fibrosis. Future Virology 2015;10:1307-19. [DOI: 10.2217/fvl.15.102] [Reference Citation Analysis]
83 Patel S, Nanavati P, Sharma J, Chavda V, Savjani J. Functional Role of Novel Indomethacin Derivatives for the Treatment of Hepatocellular Carcinoma Through Inhibition of Platelet-Derived Growth Factor. Arch Med Res. 2021;. [PMID: 33551224 DOI: 10.1016/j.arcmed.2021.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Zhou X, Sun P, Lucendo-Villarin B, Angus AG, Szkolnicka D, Cameron K, Farnworth SL, Patel AH, Hay DC. Modulating innate immunity improves hepatitis C virus infection and replication in stem cell-derived hepatocytes. Stem Cell Reports. 2014;3:204-214. [PMID: 25068132 DOI: 10.1016/j.stemcr.2014.04.018] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
85 Wang M, Scapaticci R, Cavagnaro M, Crocco L. Towards a Microwave Imaging System for Continuous Monitoring of Liver Tumor Ablation: Design and In Silico Validation of an Experimental Setup. Diagnostics (Basel) 2021;11:866. [PMID: 34065015 DOI: 10.3390/diagnostics11050866] [Reference Citation Analysis]
86 Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget 2015;6:37200-15. [PMID: 26468984 DOI: 10.18632/oncotarget.5808] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
87 Wu CH, Wu X, Zhang HW. Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor. J Surg Res. 2016;206:371-379. [PMID: 27884331 DOI: 10.1016/j.jss.2016.08.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
88 Poortahmasebi V, Poorebrahim M, Najafi S, Jazayeri SM, Alavian SM, Arab SS, Ghavami S, Alavian SE, Rezaei Moghadam A, Amiri M. How Hepatitis C Virus Leads to Hepatocellular Carcinoma: A Network-Based Study. Hepat Mon 2016;16:e36005. [PMID: 27148389 DOI: 10.5812/hepatmon.36005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
89 Yuan S, Gong Y, Chen R, Du J, Zhang H, Chen T. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway. Biomed Pharmacother 2020;132:110867. [PMID: 33075668 DOI: 10.1016/j.biopha.2020.110867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Fatima G, Mathan G, Kumar V. The HBx protein of hepatitis B virus regulates the expression, intracellular distribution and functions of ribosomal protein S27a. J Gen Virol 2012;93:706-15. [PMID: 22158882 DOI: 10.1099/vir.0.035691-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
91 Guo J, Seo Y, Ren S, Hong S, Lee D, Kim S, Jiang Y. Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY) 2016;41:1960-72. [PMID: 27318936 DOI: 10.1007/s00261-016-0807-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
92 Insuasty D, Castillo J, Becerra D, Rojas H, Abonia R. Synthesis of Biologically Active Molecules through Multicomponent Reactions. Molecules 2020;25:E505. [PMID: 31991635 DOI: 10.3390/molecules25030505] [Cited by in Crossref: 35] [Cited by in F6Publishing: 11] [Article Influence: 17.5] [Reference Citation Analysis]
93 Wu DB, Wang ML, Chen EQ, Tang H. New insights into the role of vitamin D in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2018;12:287-94. [PMID: 29140126 DOI: 10.1080/17474124.2018.1406307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
94 Chen Q, Shang W, Zeng C, Wang K, Liang X, Chi C, Liang X, Yang J, Fang C, Tian J. Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes. Oncotarget. 2017;8:32741-32751. [PMID: 28416757 DOI: 10.18632/oncotarget.15642] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
95 Li J, Xu J, Li Z. Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. Transl Oncol 2021;14:101116. [PMID: 33975180 DOI: 10.1016/j.tranon.2021.101116] [Reference Citation Analysis]
96 Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, Li L, Li H, Tian T, Wu D, Shen F, Xing J, Chen ZN. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One 2011;6:e26168. [PMID: 22043308 DOI: 10.1371/journal.pone.0026168] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
97 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015; 7(12): 1708-1717 [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
98 Dorna Mde S, Santos LA, Gondo FF, Augusti L, de Campos Franzoni L, Sassaki LY, Romeiro FG, de Paiva SA, Minicucci MF, Silva GF. Phase angle is associated with advanced fibrosis in patients chronically infected with hepatitis C virus. Life Sci. 2016;154:30-33. [PMID: 26896689 DOI: 10.1016/j.lfs.2016.02.061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
99 Wang R, Duan YL. Progress in understanding the role of leptin in the pathogenesis and treatment of chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2012; 20(10): 831-836 [DOI: 10.11569/wcjd.v20.i10.831] [Reference Citation Analysis]
100 Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z, Zhang Y, Hu H, Fan D, Nie Y. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2013;57:610-624. [PMID: 22911555 DOI: 10.1002/hep.26029] [Cited by in Crossref: 138] [Cited by in F6Publishing: 129] [Article Influence: 15.3] [Reference Citation Analysis]
101 Kim SY, Hwangbo H, Lee H, Park C, Kim GY, Moon SK, Yun SJ, Kim WJ, Cheong J, Choi YH. Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway. Int J Mol Sci 2020;21:E5502. [PMID: 32752099 DOI: 10.3390/ijms21155502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
102 Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol 2020; 26(33): 4900-4918 [PMID: 32952338 DOI: 10.3748/wjg.v26.i33.4900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
103 Wang K, Fan Y, Chen G, Wang Z, Kong D, Zhang P. MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models. Biochemical and Biophysical Research Communications 2016;474:330-7. [DOI: 10.1016/j.bbrc.2016.04.099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
104 Mao Y, Pei N, Chen X, Chen H, Yan R, Bai N, Li A, Li J, Zhang Y, Du H, Chen B, Sumners C, Wang X, Wang S, Li H. Angiotensin 1-7 Overexpression Mediated by a Capsid-optimized AAV8 Vector Leads to Significant Growth Inhibition of Hepatocellular Carcinoma In vivo. Int J Biol Sci 2018;14:57-68. [PMID: 29483825 DOI: 10.7150/ijbs.22235] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
105 Jie M, Hai-xia L, Fei-fei T, Shu-ling L, Tian-yi F, Xue-qian W, Qing-guo W, Fa-feng C. Systematic Investigation of Berberine for Treating Hepatocellular Carcinoma Based on Network Pharmacology. Digital Chinese Medicine 2019;2:127-35. [DOI: 10.1016/j.dcmed.2019.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
106 Merle P. Pragmatic tools for the prediction and potential early diagnosis of hepatitis B virus-related hepatocellular carcinoma? Clin Res Hepatol Gastroenterol 2021;45:101722. [PMID: 34146725 DOI: 10.1016/j.clinre.2021.101722] [Reference Citation Analysis]
107 Lu S, Dai M, Hu X, Yi H, Zhang Y. A new survival model based on ion channel genes for prognostic prediction in hepatocellular carcinoma. Genomics 2021;113:171-82. [PMID: 33340691 DOI: 10.1016/j.ygeno.2020.12.028] [Reference Citation Analysis]
108 Yang Y, Zhang D, Feng N, Chen G, Liu J, Chen G, Zhu Y. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. Gastroenterology. 2014;147:1031-1042. [PMID: 25127680 DOI: 10.1053/j.gastro.2014.08.005] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 8.9] [Reference Citation Analysis]
109 Wang X, Liao X, Huang K, Zeng X, Liu Z, Zhou X, Yu T, Yang C, Yu L, Wang Q, Han C, Zhu G, Ye X, Peng T. Clustered microRNAs hsa-miR-221-3p/hsa-miR-222-3p and their targeted genes might be prognostic predictors for hepatocellular carcinoma. J Cancer 2019;10:2520-33. [PMID: 31258758 DOI: 10.7150/jca.29207] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
110 de Carvalho FM, de Almeida Pereira T, Gonçalves PL, Jarske RD, Pereira FE, Louro ID. Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil. Mol Biol Rep 2013;40:4883-7. [PMID: 23649769 DOI: 10.1007/s11033-013-2587-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
111 You Y, Wang Z, Ran H, Zheng Y, Wang D, Xu J, Wang Z, Chen Y, Li P. Nanoparticle-enhanced synergistic HIFU ablation and transarterial chemoembolization for efficient cancer therapy. Nanoscale 2016;8:4324-39. [PMID: 26837265 DOI: 10.1039/c5nr08292g] [Cited by in Crossref: 57] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
112 Egawa M, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Furuta K, Kamada Y, Chatani N, Hamano M, Kiso S, Hikita H, Tatsumi T, Eguchi H, Nagano H, Doki Y, Mori M, Takehara T. Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma: FoxM1 as a universal prognostic biomarker for HCC. Hepatol Res 2017;47:1196-205. [DOI: 10.1111/hepr.12854] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
113 Sun Y, Lu Y, Li T, Xie L, Deng Y, Li S, Qin X. Interferon Gamma +874T/A Polymorphism Increases the Risk of Hepatitis Virus-Related Diseases: Evidence from a Meta-Analysis. PLoS One 2015;10:e0121168. [PMID: 25939029 DOI: 10.1371/journal.pone.0121168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
114 Chen Y, Chen HN, Wang K, Zhang L, Huang Z, Liu J, Zhang Z, Luo M, Lei Y, Peng Y, Zhou ZG, Wei Y, Huang C. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol 2019;70:66-77. [PMID: 30287340 DOI: 10.1016/j.jhep.2018.09.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
115 Chen W, Zhou C, Zhang W, Atyah M, Yin Y, Guo L, Tang W, Dong Q, Ye Q, Ren N. Association of WWOX rs9926344 polymorphism with poor prognosis of hepatocellular carcinoma. J Cancer 2018;9:1239-47. [PMID: 29675105 DOI: 10.7150/jca.23808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Wang AG, Song YN, Chen J, Li HL, Dong JY, Cui HP, Yao L, Li XF, Gao WT, Qiu ZW, Wang FJ, Wang JY. Activation of RAS/ERK alone is insufficient to inhibit RXRα function and deplete retinoic acid in hepatocytes. Biochem Biophys Res Commun 2014;452:801-7. [PMID: 25218146 DOI: 10.1016/j.bbrc.2014.09.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
117 Hussein NAEM, El-toukhy MAE, Kazem AH, Ali ME, Ahmad MAE, Ghazy HMR, El-din AMG. Protective and therapeutic effects of cannabis plant extract on liver cancer induced by dimethylnitrosamine in mice. Alexandria Journal of Medicine 2014;50:241-51. [DOI: 10.1016/j.ajme.2014.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
119 Li Y, Chen X, Lu H. Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. Oncol Res 2016;24:511-9. [PMID: 28281971 DOI: 10.3727/096504016X14719078133483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
120 Chen MB, Zhou ZT, Yang L, Wei MX, Tang M, Ruan TY, Xu JY, Zhou XZ, Chen G, Lu PH. KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms. Oncotarget 2016;7:17047-59. [PMID: 26933997 DOI: 10.18632/oncotarget.7742] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
121 Singh AK, Kumar R, Pandey AK. Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. Curr Chem Genom Transl Med. 2018;12:9-26. [PMID: 30069430 DOI: 10.2174/2213988501812010009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
122 Zhang L, Yang L, Liu X, Chen W, Chang L, Chen L, Loera S, Chu P, Huang WC, Liu YR. MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology. 2013;57:1919-1930. [PMID: 23175432 DOI: 10.1002/hep.26162] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
123 Xu W, Kuang Y, Wang D, Li Z, Xia R. Irigenin exerts anticancer effects on human liver cancer cells via induction of mitochondrial apoptosis and cell cycle arrest. Appl Biol Chem 2021;64. [DOI: 10.1186/s13765-020-00570-6] [Reference Citation Analysis]
124 Zhang X, Yin S, Ma K. Bioinformatics analysis of different candidate genes involved in hepatocellular carcinoma induced by HepG2 cells or tumor cells of patients. J Int Med Res 2020;48:300060520932112. [PMID: 32567431 DOI: 10.1177/0300060520932112] [Reference Citation Analysis]
125 Chen B, Pan Y, Xu X, Wu F, Zheng X, Chen SY, Zhao YT, Huang Z, Cheng SH, Liu JX, Wang WH, Li YX. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment. Biomed Pharmacother 2020;128:110284. [PMID: 32480224 DOI: 10.1016/j.biopha.2020.110284] [Reference Citation Analysis]
126 Li Y, Ye Y, Feng B, Qi Y. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway. J Cell Biochem. 2017;118:4498-4507. [PMID: 28464252 DOI: 10.1002/jcb.26107] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 13.8] [Reference Citation Analysis]
127 Cheng S, Li E, Lok AS. Predictors and Barriers to Hepatitis B Screening in a Midwest Suburban Asian Population. J Community Health 2017;42:533-43. [PMID: 27770375 DOI: 10.1007/s10900-016-0285-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
128 Yang N, Wang L, Chen T, Liu R, Liu Z, Zhang L. ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression. J Cancer 2020;11:5831-9. [PMID: 32913476 DOI: 10.7150/jca.45190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
129 Yuan W, Tao R, Huang D, Yan W, Shen G, Ning Q. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. Aging (Albany NY) 2021;13:3969-93. [PMID: 33495404 DOI: 10.18632/aging.202365] [Reference Citation Analysis]
130 Yang JD, Malhi H. Green tea consumption: A potential chemopreventive measure for hepatocellular carcinoma? Hepatology 2018;67:10-2. [PMID: 28833368 DOI: 10.1002/hep.29481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
131 Chen J, Wang T, Xu S, Lin A, Yao H, Xie W, Zhu Z, Xu J. Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents. European Journal of Medicinal Chemistry 2017;132:173-83. [DOI: 10.1016/j.ejmech.2017.03.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
132 Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, Larson JJ, Therneau TM, Roberts LR, Kim WR. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc 2012;87:9-16. [PMID: 22212963 DOI: 10.1016/j.mayocp.2011.07.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
133 Wang J, Zhou Y, Fei X, Chen X, Chen R, Zhu Z, Chen Y. Integrative bioinformatics analysis identifies ROBO1 as a potential therapeutic target modified by miR-218 in hepatocellular carcinoma. Oncotarget 2017;8:61327-37. [PMID: 28977866 DOI: 10.18632/oncotarget.18099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
134 Li X, Cheng T, He Y, Zhou S, Wang Y, Zhang K, Yu P. High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway. Life Sci. 2019;232:116602. [PMID: 31251997 DOI: 10.1016/j.lfs.2019.116602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
135 Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939-946. [PMID: 24950276 DOI: 10.1097/sla.0000000000000747] [Cited by in Crossref: 128] [Cited by in F6Publishing: 66] [Article Influence: 18.3] [Reference Citation Analysis]
136 Zhou Q, Zhang W, Wang Z, Liu S. Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma. BMC Cancer. 2019;19:731. [PMID: 31340767 DOI: 10.1186/s12885-019-5936-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
137 Yu G, Xiao Q, Ma XP, Chen X, Shi Z, Zhang LY, Chen H, Zhang P, Ding DL, Huang HX, Saiyin H, Chen TY, Lu PX, Wang NJ, Yu H, Sun J, Conran C, Zheng SL, Xu J, Yu L, Jiang DK. miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients. Tumour Biol 2016;37:8961-72. [PMID: 26753964 DOI: 10.1007/s13277-015-4752-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
138 Hu B, Xiong Y, Ni R, Wei L, Jiang D, Wang G, Wu D, Xu T, Zhao F, Zhu M. The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem. 2014;396:175-185. [PMID: 25081333 DOI: 10.1007/s11010-014-2153-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
139 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
140 Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:281-290. [PMID: 21497745 DOI: 10.1016/j.bpg.2011.02.009] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 10.4] [Reference Citation Analysis]
141 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
142 Wang L, Yao M, Dong Z, Zhang Y, Yao D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2014;35:9-20. [PMID: 24006223 DOI: 10.1007/s13277-013-1141-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
143 Wu Q, Wang SP, Sun XX, Tao YF, Yuan XQ, Chen QM, Dai L, Li CL, Zhang JY, Yang AL. HuaChanSu suppresses tumor growth and interferes with glucose metabolism in hepatocellular carcinoma cells by restraining Hexokinase-2. Int J Biochem Cell Biol 2022;142:106123. [PMID: 34826616 DOI: 10.1016/j.biocel.2021.106123] [Reference Citation Analysis]
144 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
145 Jia X, Dang S, Cheng Y, Zhang X, Li M, Li Y, Li S. Effects of saikosaponin-d on syndecan-2, matrix metalloproteinases and tissue inhibitor of metalloproteinases-2 in rats with hepatocellular carcinoma. J Tradit Chin Med 2012;32:415-22. [PMID: 23297566 DOI: 10.1016/s0254-6272(13)60048-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
146 Zhong L, Wang Y, Cheng Y, Wang W, Lu B, Zhu L, Ma Y. Circular RNA circC3P1 suppresses hepatocellular carcinoma growth and metastasis through miR-4641/PCK1 pathway. Biochem Biophys Res Commun. 2018;499:1044-1049. [PMID: 29608893 DOI: 10.1016/j.bbrc.2018.03.221] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 17.0] [Reference Citation Analysis]
147 Schneider-yin X, van Tuyll van Serooskerken A, Siegesmund M, Went P, Barman-aksözen J, Bladergroen RS, Komminoth P, Cloots RH, Winnepenninckx VJ, zur Hausen A, Weber M, Driessen A, Poblete-gutiérrez P, Bauer P, Schroeder C, van Geel M, Minder EI, Frank J. Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias. Journal of Hepatology 2015;62:734-8. [DOI: 10.1016/j.jhep.2014.11.029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
148 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
149 Wang J, He H, Jiang Q, Wang Y, Jia S. CBX6 Promotes HCC Metastasis Via Transcription Factors Snail/Zeb1-Mediated EMT Mechanism. Onco Targets Ther 2020;13:12489-500. [PMID: 33311989 DOI: 10.2147/OTT.S257363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Subramaniam A, Loo SY, Rajendran P, Manu KA, Perumal E, Li F, Shanmugam MK, Siveen KS, Park JI, Ahn KS, Hui KM, Kumar AP, Sethi G. An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Apoptosis 2013;18:1175-87. [PMID: 23700228 DOI: 10.1007/s10495-013-0851-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
151 Ng KT, Guo DY, Cheng Q, Geng W, Ling CC, Li CX, Liu XB, Ma YY, Lo CM, Poon RT, Fan ST, Man K. A garlic derivative, S-allylcysteine (SAC), suppresses proliferation and metastasis of hepatocellular carcinoma. PLoS One 2012;7:e31655. [PMID: 22389672 DOI: 10.1371/journal.pone.0031655] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
152 Cui X, Li Z, Gao J, Gao PJ, Ni YB, Zhu JY. Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a. Oncotarget. 2016;7:65052-65066. [PMID: 27542259 DOI: 10.18632/oncotarget.11350] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
153 Li R, Shui L, Jia J, Wu C. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. Front Genet 2020;11:906. [PMID: 32922438 DOI: 10.3389/fgene.2020.00906] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Swet JH, Pacheco HJ, Iannitti DA, El-Ghanam A, McKillop IH. A silica-calcium-phosphate nanocomposite drug delivery system for the treatment of hepatocellular carcinoma: in vivo study. J Biomed Mater Res B Appl Biomater 2014;102:190-202. [PMID: 23913418 DOI: 10.1002/jbm.b.32995] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
155 Williams JB, Hüppner A, Mulrooney-Cousins PM, Michalak TI. Differential Expression of Woodchuck Toll-Like Receptors 1-10 in Distinct Forms of Infection and Stages of Hepatitis in Experimental Hepatitis B Virus Infection. Front Microbiol 2018;9:3007. [PMID: 30581424 DOI: 10.3389/fmicb.2018.03007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
156 Colagrande S, Pradella S, Lucarini S, Marra F. Transient Hepatic Parenchymal Enhancement detected at dynamic imaging: A short instruction manual for the clinician. Digestive and Liver Disease 2012;44:363-8. [DOI: 10.1016/j.dld.2011.10.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
157 Li L, Chen J, Xu W, Ding X, Wang X, Liang J. Clinical characteristics of hepatocellular carcinoma patients with normal serum alpha-fetoprotein level: A study of 112 consecutive cases. Asia Pac J Clin Oncol 2018;14:e336-40. [PMID: 29071776 DOI: 10.1111/ajco.12816] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Ramaekers P, de Greef M, van Breugel JMM, Moonen CTW, Ries M. Increasing the HIFU ablation rate through an MRI-guided sonication strategy using shock waves: feasibility in the in vivo porcine liver. Phys Med Biol 2016;61:1057-77. [DOI: 10.1088/0031-9155/61/3/1057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
159 Lang UE, Kocabayoglu P, Cheng GZ, Ghiassi-Nejad Z, Muñoz U, Vetter D, Eckstein DA, Hannivoort RA, Walsh MJ, Friedman SL. GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene 2013;32:4557-64. [PMID: 23085750 DOI: 10.1038/onc.2012.457] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
160 Bharati S, Rishi P, Koul A. Azadirachta indica exhibits chemopreventive action against hepatic cancer: Studies on associated histopathological and ultrastructural changes. Microsc Res Tech. 2012;75:586-595. [PMID: 21998015 DOI: 10.1002/jemt.21095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
161 Zhu W, Butrin A, Melani RD, Doubleday PF, Ferreira GM, Tavares MT, Habeeb Mohammad TS, Beaupre BA, Kelleher NL, Moran GR, Liu D, Silverman RB. Rational Design, Synthesis, and Mechanism of (3S,4R)-3-Amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic Acid: Employing a Second-Deprotonation Strategy for Selectivity of Human Ornithine Aminotransferase over GABA Aminotransferase. J Am Chem Soc 2022. [PMID: 35293728 DOI: 10.1021/jacs.2c00924] [Reference Citation Analysis]
162 Kim DH, Oh HG, Park WH, Jeon DC, Lim KM, Kim HJ, Jang BK, Song KS. Detection of Alpha-Fetoprotein in Hepatocellular Carcinoma Patient Plasma with Graphene Field-Effect Transistor. Sensors (Basel) 2018;18:E4032. [PMID: 30463232 DOI: 10.3390/s18114032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
163 Ni J, Liu S, Xu L, Sun H, Chen Y. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:653-9. [DOI: 10.1007/s00432-012-1369-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
164 Neamatallah M, Serria MS, El‐bendary M, El‐gilany A, Alhawarey A, Abed S, Setate YA, Ammar OA. Association of Vitamin D Gene Polymorphisms With HCV Infection Outcome. Br J Biomed Sci 2022;79:10237. [DOI: 10.3389/bjbs.2021.10237] [Reference Citation Analysis]
165 Ding M, Pan J, Guo Z, Liu Q, Yang C, Mao L. SATB1 is a Novel Molecular Target for Cancer Therapy. Cancer Investigation 2018;36:28-36. [DOI: 10.1080/07357907.2018.1423688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
166 Nguyen CB, Kotturi H, Waris G, Mohammed A, Chandrakesan P, May R, Sureban S, Weygant N, Qu D, Rao CV, Dhanasekaran DN, Bronze MS, Houchen CW, Ali N. (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Res 2016;76:4887-96. [PMID: 27287718 DOI: 10.1158/0008-5472.CAN-15-2722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
167 Zhu L, Sun Y, Zhang S, Wang L. Rap2B knockdown suppresses malignant progression of hepatocellular carcinoma by inactivating the PTEN/PI3K/Akt and ERK1/2 pathways. Mol Cell Biochem 2020;466:55-63. [PMID: 32052247 DOI: 10.1007/s11010-020-03687-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
168 Kim LH, Cheong HS, Namgoong S, Kim JO, Kim JH, Park BL, Cho SW, Park NH, Cheong JY, Koh I. Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci of STAT4 and HLA-DQ in a Korean population. Infect Genet Evol. 2015;33:72-76. [PMID: 25913043 DOI: 10.1016/j.meegid.2015.04.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
169 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
170 Hu S, Tao R, Wang S, Wang C, Zhao X, Zhao H, Li L, Zhu S, He Y, Jiang X, Gao Y. MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. Tumor Biol 2015;36:5467-72. [DOI: 10.1007/s13277-015-3213-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
171 Huang Y, Nie M, Li C, Zhao Y, Li J, Zhou L, Wang L. RLIM suppresses hepatocellular carcinogenesis by up-regulating p15 and p21. Oncotarget 2017;8:83075-87. [PMID: 29137325 DOI: 10.18632/oncotarget.20904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Xu Q, Li YC, Du C, Wang LN, Xiao YH. Effects of Apigenin on the Expression of LOX-1, Bcl-2, and Bax in Hyperlipidemia Rats. Chem Biodivers 2021;18:e2100049. [PMID: 34118114 DOI: 10.1002/cbdv.202100049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Chen J, Xuan Z, Song W, Han W, Chen H, Du Y, Xie H, Zhao Y, Zheng S, Song P. EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation. Oncogene 2021;40:163-76. [PMID: 33097858 DOI: 10.1038/s41388-020-01522-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Zhao X, Hu S, Wang L, Zhang Q, Zhu X, Zhao H, Wang C, Tao R, Guo S, Wang J, Xu J, He Y, Gao Y. Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations. PLoS One 2014;9:e106841. [PMID: 25198338 DOI: 10.1371/journal.pone.0106841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
175 Wu L, Feng J, Li J, Yu Q, Ji J, Wu J, Dai W, Guo C. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother 2021;133:111036. [PMID: 33378947 DOI: 10.1016/j.biopha.2020.111036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
176 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
177 Lei B, Zhou J, Xuan X, Tian Z, Zhang M, Gao W, Lin Y, Ni B, Pang H, Fan W. Circular RNA expression profiles of peripheral blood mononuclear cells in hepatocellular carcinoma patients by sequence analysis. Cancer Med 2019;8:1423-33. [PMID: 30714679 DOI: 10.1002/cam4.2010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
178 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
179 Oberley CC, Bilger A, Drinkwater NR. Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 2015;54:959-70. [PMID: 24838184 DOI: 10.1002/mc.22165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
180 Zhu X, Wang F, Lin MC, Tian L, Fan W, Ng SS, Liu M, Huang J, Xu Z, Li D, Kung H. The 3' UTR variants in the GRP78 are not associated with overall survival in resectable hepatocellular carcinoma. PLoS One 2011;6:e17783. [PMID: 21445355 DOI: 10.1371/journal.pone.0017783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
181 Kanda M, Murotani K, Sugimoto H, Miwa T, Umeda S, Suenaga M, Hayashi M, Hattori N, Tanaka C, Kobayashi D, Yamada S, Fujiwara M, Kodera Y. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget 2017;8:71070-9. [PMID: 29050343 DOI: 10.18632/oncotarget.20369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
182 Yang JD, Dai J, Singal AG, Gopal P, Addissie BD, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Gores GJ, Feng Z, Marrero JA, Roberts LR. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. Cancer Epidemiol Biomarkers Prev 2017;26:1085-92. [PMID: 28258053 DOI: 10.1158/1055-9965.EPI-16-0747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
183 Zhu G, Tao T, Zhang D, Liu X, Qiu H, Han L, Xu Z, Xiao Y, Cheng C, Shen A. O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression. Glycobiology 2016;26:820-33. [DOI: 10.1093/glycob/cww025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
184 Chen PM, Li JR, Liu CC, Tang FY, Chiang EI. Metabolic Pathways Enhancement Confers Poor Prognosis in p53 Exon Mutant Hepatocellular Carcinoma. Cancer Inform 2020;19:1176935119899913. [PMID: 31933519 DOI: 10.1177/1176935119899913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Li H, Hai Z, Zou L, Zhang L, Wang L, Wang L, Liang G. Simultaneous enhancement of T1 and T2 magnetic resonance imaging of liver tumor at respective low and high magnetic fields. Theranostics 2022;12:410-7. [PMID: 34987653 DOI: 10.7150/thno.67155] [Reference Citation Analysis]
186 Zhang Z, Miao L, Lv C, Sun H, Wei S, Wang B, Huang C, Jiao B. Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells. Cell Death Dis. 2013;4:e657. [PMID: 23744357 DOI: 10.1038/cddis.2013.182] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
187 Siddiqui S, Ahmad R, Khan MA, Upadhyay S, Husain I, Srivastava AN. Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells. Sci Rep 2019;9:245. [PMID: 30664656 DOI: 10.1038/s41598-018-36475-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
188 Wan J, Liu H, Yang L, Ma L, Liu J, Ming L. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. Int J Cancer 2019;144:2489-500. [PMID: 30125344 DOI: 10.1002/ijc.31816] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
189 Deng L, Yang SB, Xu FF, Zhang JH. Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. J Exp Clin Cancer Res. 2015;34:18. [PMID: 25884472 DOI: 10.1186/s13046-015-0136-7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 193] [Article Influence: 26.3] [Reference Citation Analysis]
190 Lai Q, Avolio AW, Lerut J, Singh G, Chan SC, Berloco PB, Tisone G, Agnes S, Chok KS, Sharr W. Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West. J Hepatol. 2012;57:974-979. [PMID: 22771712 DOI: 10.1016/j.jhep.2012.06.033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
191 Lukasik Z, Elewaut D, Venken K. MAIT Cells Come to the Rescue in Cancer Immunotherapy? Cancers (Basel) 2020;12:E413. [PMID: 32053875 DOI: 10.3390/cancers12020413] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
192 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
193 Ai X, Xiang L, Huang Z, Zhou S, Zhang S, Zhang T, Jiang T. Overexpression of PIK3R1 promotes hepatocellular carcinoma progression. Biol Res 2018;51:52. [PMID: 30497511 DOI: 10.1186/s40659-018-0202-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
194 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
195 Qiu H, Liu F, Tao T, Zhang D, Liu X, Zhu G, Xu Z, Ni R, Shen A. Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma. Mol Carcinog 2017;56:258-71. [PMID: 27175940 DOI: 10.1002/mc.22490] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
196 Xu G, Zhu Y, Liu H, Liu Y, Zhang X. Long Non-Coding RNA KCNQ1OT1 Promotes Progression of Hepatocellular Carcinoma by miR-148a-3p/IGF1R Axis. Technol Cancer Res Treat 2020;19:1533033820980117. [PMID: 33349156 DOI: 10.1177/1533033820980117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Jeon T, Ko MJ, Seo YR, Jung SJ, Seo D, Park SY, Park KU, Kim KS, Kim M, Seo JH, Park IC, Kim MJ, Bae JH, Song DK, Cho CH, Lee JH, Lee YH. Silencing CDCA8 Suppresses Hepatocellular Carcinoma Growth and Stemness via Restoration of ATF3 Tumor Suppressor and Inactivation of AKT/β-Catenin Signaling. Cancers (Basel) 2021;13:1055. [PMID: 33801424 DOI: 10.3390/cancers13051055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Guerra S, Mamede AC, Carvalho MJ, Laranjo M, Tralhão JG, Abrantes AM, Maia CJ, Botelho MF. Liver diseases: what is known so far about the therapy with human amniotic membrane? Cell Tissue Bank 2016;17:653-63. [PMID: 27550013 DOI: 10.1007/s10561-016-9579-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
199 Li Y, Hu Y, Xiao J, Liu G, Li X, Zhao Y, Tan H, Shi H, Cheng D. Investigation of SP94 Peptide as a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy. Sci Rep 2016;6:33511. [PMID: 27649935 DOI: 10.1038/srep33511] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
200 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
201 Jun CH, Ki HS, Lee KH, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19:70-77. [PMID: 23593612 DOI: 10.3350/cmh.2013.19.1.70] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
202 Yao S, Johnson C, Hu Q, Yan L, Liu B, Ambrosone CB, Wang J, Liu S. Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations. Oncotarget. 2016;7:40491-40499. [PMID: 27246981 DOI: 10.18632/oncotarget.9636] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
203 Yang Y, Guo J, Hao Y, Wang F, Li F, Shuang S, Wang J. Silencing of karyopherin α2 inhibits cell growth and survival in human hepatocellular carcinoma. Oncotarget 2017;8:36289-304. [PMID: 28422734 DOI: 10.18632/oncotarget.16749] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
204 Chen L, Sun T, Kan X, Chen S, Ren Y, Cao Y, Yan L, Liang B, Xiong B, Zheng C. Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study. J Int Med Res 2020;48:300060520944309. [PMID: 33050765 DOI: 10.1177/0300060520944309] [Reference Citation Analysis]
205 Ramos-tovar E, Muriel P. Does Nutrition Matter in Liver Disease? Liver Pathophysiology. Elsevier; 2017. pp. 743-59. [DOI: 10.1016/b978-0-12-804274-8.00053-9] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
206 Ding SM, Lu AL, Lu JF, Chen XL, Edoo MIA, Zhou L, Xie HY, Zheng SS, Li QY. Macrovascular Endothelial Cells Enhance the Motility of Liver Cancer Cells by Up-regulation of MMP-3, Activation of Integrin/FAK Signaling Pathway and Induction of Non-classical Epithelial-mesenchymal Transition. J Cancer 2020;11:2044-59. [PMID: 32127932 DOI: 10.7150/jca.38209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Tachi K, Agyei-Nkansah A, Archampong T. Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. Pan Afr Med J 2020;36:43. [PMID: 32774619 DOI: 10.11604/pamj.2020.36.43.21085] [Reference Citation Analysis]
208 Qi X, Li G, Liu D, Motamarry A, Huang X, Wolfe AM, Helke KL, Haemmerich D, Staveley-O'Carroll KF, Kimchi ET. Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer. Cancer Biol Ther 2015;16:1812-9. [PMID: 26537481 DOI: 10.1080/15384047.2015.1095412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
209 Ji H, Yu J, Liu A. Structural characterization of a low molecular weight polysaccharide from Grifola frondosa and its antitumor activity in H22 tumor-bearing mice. Journal of Functional Foods 2019;61:103472. [DOI: 10.1016/j.jff.2019.103472] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
210 Fan L, Xiao Q, Chen Y, Chen G, Duan J, Tao W. Pekinenin E Inhibits the Growth of Hepatocellular Carcinoma by Promoting Endoplasmic Reticulum Stress Mediated Cell Death. Front Pharmacol 2017;8:424. [PMID: 28706487 DOI: 10.3389/fphar.2017.00424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
211 Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2016;46:58-71. [PMID: 26265000 DOI: 10.1111/hepr.12568] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
212 Zhong W, Liu H, Deng L, Chen G, Liu Y. HBO1 overexpression is important for hepatocellular carcinoma cell growth. Cell Death Dis 2021;12:549. [PMID: 34039960 DOI: 10.1038/s41419-021-03818-1] [Reference Citation Analysis]
213 Mizuguchi T, Mitaka T, Hirata K. Role of Branched Chain Amino Acids in Cellular and Organ Damage: The Prognostic Significance of the Preoperative Branched Chain Amino Acid to Tyrosine Ratio. In: Rajendram R, Preedy VR, Patel VB, editors. Branched Chain Amino Acids in Clinical Nutrition. New York: Springer; 2015. pp. 65-77. [DOI: 10.1007/978-1-4939-1914-7_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
214 Chen X, Hu X, Hu J, Qiu Z, Yuan M, Zheng G. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice. Mol Pharm 2020;17:738-47. [PMID: 31904241 DOI: 10.1021/acs.molpharmaceut.9b00428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
215 Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, Lammert F, Coenen M, Krämer B, Körner C. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One. 2011;6:e27087. [PMID: 22087248 DOI: 10.1371/journal.pone.0027087] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 7.5] [Reference Citation Analysis]
216 Straub K, Husen P, Baba HA, Trippler M, Wedemeyer H, Herzer K. Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice. Cancer Med 2019;8:3793-802. [PMID: 31144474 DOI: 10.1002/cam4.2162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
217 Benzoubir N, Mussini C, Lejamtel C, Dos Santos A, Guillaume C, Desterke C, Samuel D, Bréchot C, Bourgeade MF, Guettier C. Gamma-smooth muscle actin expression is associated with epithelial-mesenchymal transition and stem-like properties in hepatocellular carcinoma. PLoS One 2015;10:e0130559. [PMID: 26110787 DOI: 10.1371/journal.pone.0130559] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
218 Kwon JH, Ahn KS, Moon YH, Park JY, Wang HJ, Choi KY, Kim G, Joh JW, Lee KG, Kang KJ. AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma. J Korean Med Sci 2015;30:1253-9. [PMID: 26339164 DOI: 10.3346/jkms.2015.30.9.1253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
219 Poojari R, Kini S, Srivastava R, Panda D. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics. Mol Pharmaceutics 2015;12:3908-23. [DOI: 10.1021/acs.molpharmaceut.5b00337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
220 Ochoa-Callejero L, Toshkov I, Menne S, Martínez A. Expression of matrix metalloproteinases and their inhibitors in the woodchuck model of hepatocellular carcinoma. J Med Virol 2013;85:1127-38. [PMID: 23595580 DOI: 10.1002/jmv.23571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
221 Ji J, Zheng X, Forgues M, Yamashita T, Wauthier EL, Reid LM, Wen X, Song Y, Wei JS, Khan J. Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma. Hepatology. 2015;62:829-840. [PMID: 25953724 DOI: 10.1002/hep.27886] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
222 Mikami D, Kobayashi M, Uwada J, Yazawa T, Kamiyama K, Nishimori K, Nishikawa Y, Nishikawa S, Yokoi S, Taniguchi T, Iwano M. AR420626, a selective agonist of GPR41/FFA3, suppresses growth of hepatocellular carcinoma cells by inducing apoptosis via HDAC inhibition. Ther Adv Med Oncol 2020;12:1758835920913432. [PMID: 33014144 DOI: 10.1177/1758835920913432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Low HM, Choi JY, Tan CH. Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. Abdom Radiol (NY) 2019;44:493-508. [PMID: 30145629 DOI: 10.1007/s00261-018-1749-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
224 Qi T, Liao J, Li Y, Peng J, Li W, Chu B, Li H, Wei Y, Qian Z. Label-free alpha fetoprotein immunosensor established by the facile synthesis of a palladium–graphene nanocomposite. Biosensors and Bioelectronics 2014;61:245-50. [DOI: 10.1016/j.bios.2014.05.021] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
225 Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis 2019;6:419-30. [PMID: 31832522 DOI: 10.1016/j.gendis.2019.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
226 Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45-54. [PMID: 23938452 DOI: 10.1038/nrgastro.2013.143] [Cited by in Crossref: 185] [Cited by in F6Publishing: 168] [Article Influence: 20.6] [Reference Citation Analysis]
227 Lafnoune A, Lee SY, Heo JY, Gourja I, Darkaoui B, Abdelkafi-Koubaa Z, Chgoury F, Daoudi K, Chakir S, Cadi R, Mounaji K, Srairi-Abid N, Marrakchi N, Shum D, Seo HR, Oukkache N. Anti-Cancer Effect of Moroccan Cobra Naja haje Venom and Its Fractions against Hepatocellular Carcinoma in 3D Cell Culture. Toxins (Basel) 2021;13:402. [PMID: 34199838 DOI: 10.3390/toxins13060402] [Reference Citation Analysis]
228 Han B, Yu YQ, Yang QL, Shen CY, Wang XJ. Kaempferol induces autophagic cell death of hepatocellular carcinoma cells via activating AMPK signaling. Oncotarget 2017;8:86227-39. [PMID: 29156790 DOI: 10.18632/oncotarget.21043] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
229 Zhang C, Liu P, Zhang C. Hepatitis B virus X protein upregulates alpha-fetoprotein to promote hepatocellular carcinoma by targeting miR-1236 and miR-329. J Cell Biochem 2020;121:2489-99. [PMID: 31680299 DOI: 10.1002/jcb.29471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
230 Liu M, Wu R, Liu X, Xu H, Chi X, Wang X, Zhan M, Wang B, Peng F, Gao X, Shi Y, Wen X, Ji Y, Jin Q, Niu J. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients. J Hepatocell Carcinoma 2020;7:219-32. [PMID: 33123501 DOI: 10.2147/JHC.S271790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
231 Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, Huang XF, Chen ZN, Bian H. HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug. Oncogene 2011;30:4410-27. [PMID: 21532623 DOI: 10.1038/onc.2011.149] [Cited by in Crossref: 112] [Cited by in F6Publishing: 109] [Article Influence: 10.2] [Reference Citation Analysis]
232 Zhang X, Wu Z, Peng Y, Li D, Jiang Y, Pan F, Li Y, Lai Y, Cui Z, Zhang K. Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Biomed Res Int 2021;2021:6651397. [PMID: 33954191 DOI: 10.1155/2021/6651397] [Reference Citation Analysis]
233 Yang B, Li M, Tang W, Liu W, Zhang S, Chen L, Xia J. Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. Nat Commun 2018;9:678. [PMID: 29445139 DOI: 10.1038/s41467-018-03024-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 16.0] [Reference Citation Analysis]
234 Yan S, Shan X, Chen K, Liu Y, Yu G, Chen Q, Zeng T, Zhu L, Dang H, Chen F, Ling J, Huang A, Tang H. LINC00052/miR-101-3p axis inhibits cell proliferation and metastasis by targeting SOX9 in hepatocellular carcinoma. Gene 2018;679:138-49. [PMID: 30098428 DOI: 10.1016/j.gene.2018.08.038] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
235 Huang J, Lu D, Xiang T, Wu X, Ge S, Wang Y, Wang J, Cheng N. MicroRNA-132-3p regulates cell proliferation, apoptosis, migration and invasion of liver cancer by targeting Sox4. Oncol Lett 2020;19:3173-80. [PMID: 32256813 DOI: 10.3892/ol.2020.11431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
236 Liu DG, Chen J, Wang HX, Li BX. Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 2016;12:4961-8. [PMID: 28105202 DOI: 10.3892/ol.2016.5344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
237 Liu H, Xu HW, Zhang YZ, Huang Y, Han GQ, Liang TJ, Wei LL, Qin CY, Qin CK. Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice. World J Gastroenterol 2015; 21(36): 10367-10374 [PMID: 26420963 DOI: 10.3748/wjg.v21.i36.10367] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
238 Shalimar, Jain S, Gamanagatti SR, Kedia S, Thakur B, Nayak B, Kaur H, Gunjan D, Paul SB, Acharya SK. Role of Indocyanine Green in Predicting Post-Transarterial Chemoembolization Liver Failure in Hepatocellular Carcinoma. J Clin Exp Hepatol 2018;8:28-34. [PMID: 29743794 DOI: 10.1016/j.jceh.2017.05.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
239 Aoki J, Kowazaki Y, Ohtsuki T, Okamoto R, Ohashi K, Hayashi S, Sakamaki H, Kohara M, Kimura K. Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation. J Gastroenterol. 2013;48:728-737. [PMID: 23011082 DOI: 10.1007/s00535-012-0676-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
240 Li J, Shi C, Shi J, Song J, Wang N. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27636. [PMID: 34871232 DOI: 10.1097/MD.0000000000027636] [Reference Citation Analysis]
241 Xia L, Huang W, Tian D, Chen Z, Zhang L, Li Y, Hu H, Liu J, Chen Z, Tang G. ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Oncogene. 2014;33:1395-1406. [PMID: 23604121 DOI: 10.1038/onc.2013.90] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
242 Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-8. [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
243 Jondal DE, Thompson SM, Butters KA, Knudsen BE, Anderson JL, Roberts LR, Callstrom MR, Woodrum DA. Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in Small-Animal Model. Radiology 2019;292:752-9. [PMID: 31335281 DOI: 10.1148/radiol.2019190115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
244 Zhang T, Liu W, Zeng XC, Jiang N, Fu BS, Guo Y, Yi HM, Li H, Zhang Q, Chen WJ, Chen GH. Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. Biomed Pharmacother 2016;84:583-91. [PMID: 27694002 DOI: 10.1016/j.biopha.2016.09.056] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
245 Ramos-Lopez O, Martinez-Lopez E, Roman S, Fierro NA, Panduro A. Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World J Gastroenterol 2015; 21(41): 11552-11566 [PMID: 26556986 DOI: 10.3748/wjg.v21.i41.11552] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
246 Cao F, Yin L. PAK1 promotes proliferation, migration and invasion of hepatocellular carcinoma by facilitating EMT via directly up-regulating Snail. Genomics 2020;112:694-702. [DOI: 10.1016/j.ygeno.2019.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
247 Fu C, Xu X, Lu W, Nie L, Yin T, Wu D. Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e17412. [PMID: 31626095 DOI: 10.1097/MD.0000000000017412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
248 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
249 Refaat R, Basha MAA, Hassan MS, Hussein RS, El Sammak AA, El Sammak DAEA, Radwan MHS, Awad NM, Saad El-Din SA, Elkholy E, Ibrahim DRD, Saleh SA, Montasser IF, Said H. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Eur Radiol. 2018;28:5356-5367. [PMID: 29948070 DOI: 10.1007/s00330-018-5425-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
250 Sarvari J, Mojtahedi Z, Taghavi SA, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, Nakamura K. Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepat Mon. 2013;13:e8351. [PMID: 24066001 DOI: 10.5812/hepatmon.8351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
251 Yu X, Tang W, Yang Y, Tang L, Dai R, Pu B, Feng C, Xia J. Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-κB signaling. Chem Biol Interact 2018;285:48-58. [PMID: 29481769 DOI: 10.1016/j.cbi.2018.02.027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
252 Yuan F, Liu J, Qiao T, Li T, Shen Q, Peng F. The Effects and Mechanisms of Periplaneta americana Extract Reversal of Multi-Drug Resistance in BEL-7402/5-FU Cells. Molecules 2016;21:E852. [PMID: 27367657 DOI: 10.3390/molecules21070852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
253 Liu J, Han P, Li M, Yan W, Liu J, Liu J, He J, Tu W, Xia Y, Zhou Z, Gong J, Liu M, Ding Q, Tian D. The histidine-rich calcium binding protein (HRC) promotes tumor metastasis in hepatocellular carcinoma and is upregulated by SATB1. Oncotarget 2015;6:6811-24. [PMID: 25762622 DOI: 10.18632/oncotarget.3049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
254 Fu XT, Shi YH, Zhou J, Peng YF, Liu WR, Shi GM, Gao Q, Wang XY, Song K, Fan J, Ding ZB. Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma. Infect Agent Cancer 2017;12:28. [PMID: 28559922 DOI: 10.1186/s13027-017-0137-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
255 Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016;39:1580-1588. [PMID: 27586657 DOI: 10.1007/s00270-016-1426-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
256 Chauhan R, Churchill ND, Mulrooney-Cousins PM, Michalak TI. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma. Oncogenesis. 2017;6:e317. [PMID: 28414318 DOI: 10.1038/oncsis.2017.22] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
257 Zhang L, Pu K, Liu X, Bae SDW, Nguyen R, Bai S, Li Y, Qiao L. The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review. Front Med (Lausanne) 2021;8:644594. [PMID: 34277651 DOI: 10.3389/fmed.2021.644594] [Reference Citation Analysis]
258 Aref MH, Aboughaleb IH, Youssef AM, El-Sharkawy YH. Hyperspectral image-based analysis of thermal damage for ex-vivo bovine liver utilizing radiofrequency ablation. Surg Oncol 2021;38:101564. [PMID: 33865183 DOI: 10.1016/j.suronc.2021.101564] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
259 Li Z, Wang C, Si G, Zhou X, Li Y, Li J, Jiao D, Han X. Image-guided microwave ablation of hepatocellular carcinoma (≤5.0 cm): is MR guidance more effective than CT guidance? BMC Cancer 2021;21:366. [PMID: 33827464 DOI: 10.1186/s12885-021-08099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Yuan JH, Yang F, Chen BF, Lu Z, Huo XS, Zhou WP, Wang F, Sun SH. The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology. 2011;54:2025-2035. [PMID: 21837748 DOI: 10.1002/hep.24606] [Cited by in Crossref: 118] [Cited by in F6Publishing: 115] [Article Influence: 11.8] [Reference Citation Analysis]
261 Liang R, Lin Y, Yuan CL, Liu ZH, Li YQ, Luo XL, Ye JZ, Ye HH. The clinical significance and biological function of large tumour suppressor 2 in hepatocellular carcinoma. Cell Prolif 2017;50. [PMID: 28247446 DOI: 10.1111/cpr.12340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
262 Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, Zhong JH, Li LQ. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget 2017;8:51810-6. [PMID: 28881690 DOI: 10.18632/oncotarget.15395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
263 Sartorius K, Sartorius B, Aldous C, Govender PS, Madiba TE. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol. 2015;39:284-290. [PMID: 25922178 DOI: 10.1016/j.canep.2015.04.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 10.7] [Reference Citation Analysis]
264 Liu Y, Lou G, Norton JT, Wang C, Kandela I, Tang S, Shank NI, Gupta P, Huang M, Avram MJ, Green R, Mazar A, Appella D, Chen Z, Huang S. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. FASEB J 2017;31:5453-65. [PMID: 28821631 DOI: 10.1096/fj.201700306RR] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
265 Liu J, Han P, Li M, Yan W, Liu J, He J, Gong J, Wang Y, Tian D. Histidine-rich calcium binding protein promotes growth of hepatocellular carcinoma in vitro and in vivo. Cancer Sci 2015;106:1288-95. [PMID: 26176291 DOI: 10.1111/cas.12743] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
266 Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Bair MJ, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML. Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. PLoS One 2018;13:e0202650. [PMID: 30180193 DOI: 10.1371/journal.pone.0202650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
267 Wang F, Fei H, Qi B, Yao S, Chang Z. Overexpression of hepatitis B x-interacting protein in HepG2 cells enhances tumor-induced angiogenesis. Mol Cell Biochem 2012;364:165-71. [DOI: 10.1007/s11010-011-1215-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
268 Saadi T, Khoury J. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies? J Clin Gastroenterol. 2018;52:353-359. [PMID: 28590324 DOI: 10.1097/mcg.0000000000000853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
269 Zhang ZY, Lu M, Liu ZK, Li H, Yong YL, Zhang RY, Chen ZN, Bian H. Rab11a regulates MMP2 expression by activating the PI3K/AKT pathway in human hepatocellular carcinoma cells. Pathol Res Pract 2020;216:153046. [PMID: 32825931 DOI: 10.1016/j.prp.2020.153046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
270 Hu G, Zhai S, Yu S, Huang Z, Gao R. Circular RNA circRHOBTB3 is downregulated in hepatocellular carcinoma and suppresses cell proliferation by inhibiting miR-18a maturation. Infect Agent Cancer 2021;16:48. [PMID: 34187598 DOI: 10.1186/s13027-021-00384-1] [Reference Citation Analysis]
271 Kudo A, Shinoda M, Ariizumi S, Kumamoto T, Katayama M, Otsubo T, Endo I, Kitagawa Y, Tanabe M, Yamamoto M; Association for Clinical Research on Surgery Group. Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402. J Cancer Res Clin Oncol 2020;146:2949-56. [PMID: 32462296 DOI: 10.1007/s00432-020-03270-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
272 Liu J, Zong G, Zhang C, Li C, Chen X, Zhang Y. Anxiety and serum catecholamines as predictors of survival and recurrence in hepatocellular carcinoma. Psychooncology 2017;26:1347-53. [PMID: 27862617 DOI: 10.1002/pon.4305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
273 Chen LC, Lee WC, Ho CL, Chang YJ, Chen SJ, Chang CH. Biodistribution, Pharmacokinetics and Efficacy of 188Re(I)-Tricarbonyl-Labeled Human Serum Albumin Microspheres in an Orthotopic Hepatoma Rat Model. In Vivo 2018;32:567-73. [PMID: 29695562 DOI: 10.21873/invivo.11277] [Reference Citation Analysis]
274 Wei H, Tang Q, Wang A, Zhang Y, Qin Z, Li W, Xu Z, Wang J, Pu J. lncRNA MAGI2-AS3 Exerts Antioncogenic Roles in Hepatocellular Carcinoma via Regulating the miR-519c-3p/TXNIP Axis. J Oncol 2021;2021:5547345. [PMID: 34484334 DOI: 10.1155/2021/5547345] [Reference Citation Analysis]
275 Maini MK, Schurich A. Platelets harness the immune response to drive liver cancer. Proc Natl Acad Sci U S A 2012;109:12840-1. [PMID: 22826219 DOI: 10.1073/pnas.1210296109] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
276 Xie K, Liu J, Zhu L, Liu Y, Pan Y, Wen J, Ma H, Zhai X, Hu Z. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol. 2013;37:998-1002. [PMID: 24103425 DOI: 10.1016/j.canep.2013.09.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
277 Memon A, Pyao Y, Jung Y, Lee JI, Lee WK. A Modified Protocol of Diethylnitrosamine Administration in Mice to Model Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5461. [PMID: 32751728 DOI: 10.3390/ijms21155461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
278 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
279 Zang H, Li Y, Zhang X, Huang G. Circ_0000517 Contributes to Hepatocellular Carcinoma Progression by Upregulating TXNDC5 via Sponging miR-1296-5p. Cancer Manag Res 2020;12:3457-68. [PMID: 32523376 DOI: 10.2147/CMAR.S244024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
280 Xu W, Kwon JH, Moon YH, Kim YB, Yu YS, Lee N, Choi KY, Kim YS, Park YK, Kim BW. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2014;140:1507-1515. [PMID: 24853275 DOI: 10.1007/s00432-014-1713-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
281 Tao R, Hu S, Wang S, Zhou X, Zhang Q, Wang C, Zhao X, Zhou W, Zhang S, Li C, Zhao H, He Y, Zhu S, Xu J, Jiang Y, Li L, Gao Y. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis 2015;36:1136-43. [PMID: 26163879 DOI: 10.1093/carcin/bgv099] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
282 Wang L, Yao M, Liu S, Yang D, Wen X, Ning J, Wang L, Zhou G, Xu Q, Chen X, Zhao J, Lu F. Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. Dis Markers 2020;2020:6036904. [PMID: 32089754 DOI: 10.1155/2020/6036904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
283 Yu Q, Qian W, Wang J, Wu Y, Zhang J, Chen W. An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population. Oncol Lett 2018;15:8088-94. [PMID: 29731916 DOI: 10.3892/ol.2018.8347] [Reference Citation Analysis]
284 Wang F, Wu Z. Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Exp Ther Med 2018;15:5371-6. [PMID: 29844803 DOI: 10.3892/etm.2018.6086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
285 Endaya B, Guan SP, Newman JP, Huynh H, Sia KC, Chong ST, Kok CYL, Chung AYF, Liu BB, Hui KM, Lam PYP. Human mesenchymal stem cells preferentially migrate toward highly oncogenic human hepatocellular carcinoma cells with activated EpCAM signaling. Oncotarget 2017;8:54629-39. [PMID: 28903370 DOI: 10.18632/oncotarget.17633] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
286 Delgado E, Okabe H, Preziosi M, Russell JO, Alvarado TF, Oertel M, Nejak-Bowen KN, Zhang Y, Monga SP. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J Hepatol 2015;62:380-7. [PMID: 25457204 DOI: 10.1016/j.jhep.2014.10.021] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
287 Yan B, Ouyang Q, Zhao Z, Cao F, Wang T, Jia X, Meng Y, Jiang S, Liu J, Chen R, Jia L, Zhang R, Wen W, Jin B, Chen S, Zhao J, Yang A. Potent killing of HBV-related hepatocellular carcinoma by a chimeric protein of anti-HBsAg single-chain antibody and truncated Bid. Biomaterials 2013;34:4880-9. [DOI: 10.1016/j.biomaterials.2013.03.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
288 Ramírez-Soto MC, Ortega-Cáceres G, Cabezas C. Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data. Vaccine 2017;35:3808-12. [PMID: 28602606 DOI: 10.1016/j.vaccine.2017.05.086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
289 Ferraris P, Chandra PK, Panigrahi R, Aboulnasr F, Chava S, Kurt R, Pawlotsky JM, Wilkens L, Osterlund P, Hartmann R, Balart LA, Wu T, Dash S. Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression. Am J Pathol 2016;186:938-51. [PMID: 26896692 DOI: 10.1016/j.ajpath.2015.11.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
290 Song FN, Duan M, Liu LZ, Wang ZC, Shi JY, Yang LX, Zhou J, Fan J, Gao Q, Wang XY. RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition. PLoS One 2014;9:e108507. [PMID: 25268581 DOI: 10.1371/journal.pone.0108507] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
291 Ma HX, Shu QH, Pan JJ, Liu D, Xu GL, Li JS, Ma JL, Jia WD, Yv JH, Ge YS. Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance. Tumour Biol 2015;36:4235-41. [PMID: 25592379 DOI: 10.1007/s13277-015-3060-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
292 Vedham V, Verma M, Mahabir S. Early-life exposures to infectious agents and later cancer development. Cancer Med 2015;4:1908-22. [PMID: 26377256 DOI: 10.1002/cam4.538] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
293 Cressman ENK, Guo C. First In Vivo Test of Thermoembolization: Turning Tissue Against Itself Using Transcatheter Chemistry in a Porcine Model. Cardiovasc Intervent Radiol 2018;41:1611-7. [PMID: 29872896 DOI: 10.1007/s00270-018-2003-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
294 Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology. 2013;58:890-901. [PMID: 23505208 DOI: 10.1002/hep.26383] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
295 Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol. 2011;85:7312-7320. [PMID: 21593143 DOI: 10.1128/jvi.00253-11] [Cited by in Crossref: 107] [Cited by in F6Publishing: 53] [Article Influence: 9.7] [Reference Citation Analysis]
296 Nguyen CB, Houchen CW, Ali N. APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Exp Biol Med (Maywood) 2017;242:242-9. [PMID: 27694285 DOI: 10.1177/1535370216672746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
297 Limaiem F, Bouhamed M, Sahraoui G, Mzabi S. Hepatocellular carcinoma: a clinicopathological study of 64 cases. Pan Afr Med J 2017;27:41. [PMID: 28761617 DOI: 10.11604/pamj.2017.27.41.9584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
298 Awuku YA, Yeboah-Afihene M. Hepatitis B At-Birth Dose Vaccine: An Urgent Call for Implementation in Ghana. Vaccines (Basel) 2018;6:E15. [PMID: 29534503 DOI: 10.3390/vaccines6010015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
299 Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36:714-723. [PMID: 23093355 DOI: 10.1007/s00270-012-0481-2] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
300 Wang FB, Rong Y, Fang M, Yuan JP, Peng CW, Liu SP, Li Y. Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles. Biomaterials 2013;34:3816-27. [PMID: 23465488 DOI: 10.1016/j.biomaterials.2013.02.018] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
301 Ogura S, Yoshida Y, Kurahashi T, Egawa M, Furuta K, Kiso S, Kamada Y, Hikita H, Eguchi H, Ogita H, Doki Y, Mori M, Tatsumi T, Takehara T. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget 2018;9:21022-35. [PMID: 29765517 DOI: 10.18632/oncotarget.24781] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
302 Jin J, Wang D, Xiao H, Wei H, Matunda C, Zhang H, Li X, Wang C, Zou C, Gao X, Zhao W, Li Q. Enhancement of DEN-induced liver tumorigenesis in heme oxygenase-1 G143H mutant transgenic mice. Biochem Biophys Res Commun 2016;481:169-75. [PMID: 27810363 DOI: 10.1016/j.bbrc.2016.10.148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
303 Lin Z, Li W, Zhang H, Wu W, Peng Y, Zeng Y, Wan Y, Wang J, Ouyang N. CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma. Tumour Biol 2016;37:3461-8. [PMID: 26449829 DOI: 10.1007/s13277-015-4172-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
304 Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590-600. [PMID: 25173447 DOI: 10.1007/s00535-014-0993-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
305 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Reference Citation Analysis]
306 Kunnimalaiyaan S, Sokolowski KM, Balamurugan M, Gamblin TC, Kunnimalaiyaan M. Xanthohumol inhibits Notch signaling and induces apoptosis in hepatocellular carcinoma. PLoS One 2015;10:e0127464. [PMID: 26011160 DOI: 10.1371/journal.pone.0127464] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
307 Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ, Roberts RO, Olson JE, Therneau TM, Roberts LR. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology. 2013;57:648-655. [PMID: 23055147 DOI: 10.1002/hep.26092] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 8.1] [Reference Citation Analysis]
308 Chen YR, Li YT, Wang MQ, Zhu SL. Prognostic significance and function of MCM10 in human hepatocellular carcinoma. Future Oncol 2021. [PMID: 34350781 DOI: 10.2217/fon-2021-0225] [Reference Citation Analysis]
309 Zhang N, Wang R, Hao J, Yang Y, Zou H, Wang Z. Mesoporous composite nanoparticles for dual-modality ultrasound/magnetic resonance imaging and synergistic chemo-/thermotherapy against deep tumors. Int J Nanomedicine 2017;12:7273-89. [PMID: 29042775 DOI: 10.2147/IJN.S144058] [Cited by in Crossref: 10] [Article Influence: 2.0] [Reference Citation Analysis]
310 Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, Kim B, Roberts LR. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:64-70. [PMID: 20831903 DOI: 10.1016/j.cgh.2010.08.019] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 12.7] [Reference Citation Analysis]
311 Wang Z, Sheng YY, Gao XM, Wang CQ, Wang XY, Lu XU, Wei JW, Zhang KL, Dong QZ, Qin LX. β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol 2015;3:936-40. [PMID: 26171210 DOI: 10.3892/mco.2015.569] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
312 Yang AL, Wu Q, Hu ZD, Wang SP, Tao YF, Wang AM, Sun YX, Li XL, Dai L, Zhang J. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling. Toxicol Appl Pharmacol 2021;431:115739. [PMID: 34619160 DOI: 10.1016/j.taap.2021.115739] [Reference Citation Analysis]
313 Lin YY, Yu MW, Lin SM, Lee SD, Chen CL, Chen DS, Chen PJ. Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma. Cancer 2017;123:3966-76. [PMID: 28662289 DOI: 10.1002/cncr.30851] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
314 Peng Z, Fang G, Peng F, Pan Z, Su Z, Tian W, Li D, Hou H. Effects of Rubiadin isolated from Prismatomeris connata on anti-hepatitis B virus activity in vitro. Phytother Res 2017;31:1962-70. [PMID: 29044868 DOI: 10.1002/ptr.5945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
315 Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, Chen R, Wang Y, Zhang B, Xia J. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol. 2012;19:3540-3546. [PMID: 22532305 DOI: 10.1245/s10434-012-2368-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
316 Jia Q, Dong Q, Qin L. CCN: core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma? Oncotarget 2016;7:1203-14. [PMID: 26497214 DOI: 10.18632/oncotarget.6209] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
317 Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013;59:1135-1138. [PMID: 23742914 DOI: 10.1016/j.jhep.2013.05.040] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
318 Lu Y, Sui J, Liu Y, Li R, Ma L, Zhang X, Qin X, Li S. Association between hypoxia-inducible factor-1α gene polymorphisms and risk of chronic hepatitis B and hepatitis B virus-related liver cirrhosis in a Chinese population: a retrospective case-control study. Gene 2015;564:96-100. [PMID: 25824382 DOI: 10.1016/j.gene.2015.03.053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
319 Zhang R, Cao Y, Bai L, Zhu C, Li R, He H, Liu Y, Wu K, Liu F, Wu J. The collagen triple helix repeat containing 1 facilitates hepatitis B virus-associated hepatocellular carcinoma progression by regulating multiple cellular factors and signal cascades. Mol Carcinog 2015;54:1554-66. [PMID: 25263696 DOI: 10.1002/mc.22229] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
320 He L, Meng D, Zhang SH, Zhang Y, Deng Z, Kong LB. microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4. Biochem Biophys Res Commun 2018;501:1060-7. [PMID: 29777702 DOI: 10.1016/j.bbrc.2018.05.108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
321 Liu T, Yao M, Liu S, Wang L, Wang L, Hou J, Ma X, Jia J, Zhao J, Zhuang H, Lu F. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget. 2017;8:16498-16506. [PMID: 28157705 DOI: 10.18632/oncotarget.14954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
322 Sitia G. Platelets Promote Liver Immunopathology Contributing to Hepatitis B Virus–Mediated Hepatocarcinogenesis. Seminars in Oncology 2014;41:402-5. [DOI: 10.1053/j.seminoncol.2014.04.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
323 Li H, Cui ML, Chen TY, Xie HY, Cui Y, Tu H, Chen FH, Ge C, Li JJ. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma. Tumour Biol 2015;36:8399-404. [PMID: 26018510 DOI: 10.1007/s13277-015-3607-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
324 Ma W, Sze KM, Chan LK, Lee JM, Wei LL, Wong CM, Lee TK, Wong CC, Ng IO. RhoE/ROCK2 regulates chemoresistance through NF-κB/IL-6/ STAT3 signaling in hepatocellular carcinoma. Oncotarget 2016;7:41445-59. [PMID: 27213590 DOI: 10.18632/oncotarget.9441] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
325 Yu L, Cheng YJ, Cheng ML, Yao YM, Zhang Q, Zhao XK, Liu HJ, Hu YX, Mu M, Wang B. Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development. Sci Rep. 2015;5:14933. [PMID: 26462556 DOI: 10.1038/srep14933] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
326 Zhang L, Chen J, Yong J, Qiao L, Xu L, Liu C. An essential role of RNF187 in Notch1 mediated metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:384. [PMID: 31477177 DOI: 10.1186/s13046-019-1382-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
327 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
328 Sun D, Lu J, Wang X, Zhang Y, Chen Z. Voltammetric aptamer based detection of HepG2 tumor cells by using an indium tin oxide electrode array and multifunctional nanoprobes. Microchim Acta 2017;184:3487-96. [DOI: 10.1007/s00604-017-2376-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
329 Estevez J, Yang JD, Leong J, Nguyen P, Giama NH, Zhang N, Ali HA, Lee M, Cheung R, Roberts L, Schwartz M, Nguyen MH. Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. Am J Gastroenterol 2019;114:80-8. [DOI: 10.1038/s41395-018-0261-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
330 Cai X, Yu L, Chen Z, Ye F, Ren Z, Jin P. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cancer Biomark 2020;28:221-30. [PMID: 32280078 DOI: 10.3233/CBM-190490] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
331 Mei Y, Liu H. IL-37: An anti-inflammatory cytokine with antitumor functions. Cancer Rep (Hoboken) 2019;2:e1151. [PMID: 32935478 DOI: 10.1002/cnr2.1151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
332 Jin J, Chung JO, Chung MY, Cho DH, Chung DJ. Clinical Characteristics, Causes and Survival in 115 Cancer Patients with Parathyroid Hormone Related Protein-mediated Hypercalcemia. J Bone Metab 2017;24:249-55. [PMID: 29259965 DOI: 10.11005/jbm.2017.24.4.249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
333 Paranaguá-Vezozzo DC, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Ann Hepatol 2014;13:386-93. [PMID: 24927609 [PMID: 24927609 DOI: 10.1016/s1665-2681(19)30845-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
334 Xing T, Huang L, Yu Z, Zhong L, Wang S, Peng Z. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma. PLoS One 2013;8:e71251. [PMID: 23940730 DOI: 10.1371/journal.pone.0071251] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
335 Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag 2015;11:1603-12. [PMID: 26527877 DOI: 10.2147/TCRM.S88208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
336 Li J, Zhang Q, Fan X, Mo W, Dai W, Feng J, Wu L, Liu T, Li S, Xu S, Wang W, Lu X, Yu Q, Chen K, Xia Y, Lu J, Zhou Y, Xu L, Guo C. The long noncoding RNA TUG1 acts as a competing endogenous RNA to regulate the Hedgehog pathway by targeting miR-132 in hepatocellular carcinoma. Oncotarget 2017;8:65932-45. [PMID: 29029483 DOI: 10.18632/oncotarget.19582] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
337 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
338 Xie HJ, Jung KH, Nam SW. Overexpression of SIRT2 contributes tumor cell growth in hepatocellular carcinomas. Mol Cell Toxicol 2011;7:367-74. [DOI: 10.1007/s13273-011-0046-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
339 Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S. Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study. J Gastroenterol. 2014;49:502-510. [PMID: 23543312 DOI: 10.1007/s00535-013-0791-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
340 Lang UE, Kocabayoglu P, Cheng GZ, Ghiassi-Nejad Z, Muñoz U, Vetter D, Eckstein DA, Hannivoort RA, Walsh MJ, Friedman SL. GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene 2013;32:4557-64. [PMID: 23085750 DOI: 10.1038/onc.2012.457] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
341 Liu X, Li T, Kong D, You H, Kong F, Tang R. Prognostic implications of alcohol dehydrogenases in hepatocellular carcinoma. BMC Cancer 2020;20:1204. [PMID: 33287761 DOI: 10.1186/s12885-020-07689-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
342 Cilurzo F, Staltari O, Patanè M, Ammendola M, Garaffo C, Di Paola ED. Nexavar(®)-related adverse reactions: Calabrian (Italy) experience for sorafenib exposition in 2012. J Pharmacol Pharmacother 2013;4:S86-9. [PMID: 24347990 DOI: 10.4103/0976-500X.120971] [Reference Citation Analysis]
343 Kuo HH, Lin RJ, Hung JT, Hsieh CB, Hung TH, Lo FY, Ho MY, Yeh CT, Huang YL, Yu J, Yu AL. High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma. Sci Rep 2017;7:10750. [PMID: 28883415 DOI: 10.1038/s41598-017-11136-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
344 Wang GY, Zhu YY, Zhang YQ. The functional role of long non-coding RNA in digestive system carcinomas. Bull Cancer 2014;101:E27-31. [PMID: 25295496 DOI: 10.1684/bdc.2014.2023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
345 Lu Z, Xia YH, Zhao M, Zhang B, Dai WT, Ding L, Hu LX, Bi JL, Jiang GL. DlgR2 knockdown boosts dendritic cell activity and inhibits hepatocellular carcinoma tumor in-situ growth. Oncotarget 2017;8:54993-5002. [PMID: 28903397 DOI: 10.18632/oncotarget.18990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
346 Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105-114. [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
347 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-S90. [PMID: 25443348 DOI: 10.1016/j.jhep.2014.07.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 15.5] [Reference Citation Analysis]
348 Amicone L, Marchetti A. Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:24. [PMID: 29971255 DOI: 10.21037/tgh.2018.04.05] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
349 Li L, Chen A, Liu B, Pan H, Yu Y, Liu Y. Preparation and pharmacokinetics of glycyrrhetinic acid and cell transmembrane peptides modified with liposomes for liver targeted-delivery. Biomed Mater 2022;17. [PMID: 35483344 DOI: 10.1088/1748-605X/ac6b73] [Reference Citation Analysis]
350 Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.J Hepatocell Carcinoma. 2019;6:151-166. [PMID: 31696097 DOI: 10.2147/JHC.S224849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
351 Li R, Wang Y, Zhang X, Feng M, Ma J, Li J, Yang X, Fang F, Xia Q, Zhang Z, Shang M, Jiang S. Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol Cancer. 2019;18:18. [PMID: 30704479 DOI: 10.1186/s12943-019-0948-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 18.0] [Reference Citation Analysis]
352 Li XD, Wang Z, Wang XR, Shao D, Zhang X, Li L, Ge MF, Chang ZM, Dong WF. Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition. Int J Nanomedicine 2019;14:3967-82. [PMID: 31239666 DOI: 10.2147/IJN.S206044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
353 Chen TW, Yin FF, Yuan YM, Guan DX, Zhang E, Zhang FK, Jiang H, Ma N, Wang JJ, Ni QZ, Qiu L, Feng J, Zhang XL, Bao Y, Wang K, Cheng SQ, Wang XF, Wang X, Li JJ, Xie D. CHML promotes liver cancer metastasis by facilitating Rab14 recycle. Nat Commun 2019;10:2510. [PMID: 31175290 DOI: 10.1038/s41467-019-10364-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
354 Liu G, Shi A, Wang N, Li M, He X, Yin C, Tu Q, Shen X, Tao Y, Wang Q, Yin H. Polyphenolic Proanthocyanidin-B2 suppresses proliferation of liver cancer cells and hepatocellular carcinogenesis through directly binding and inhibiting AKT activity. Redox Biol 2020;37:101701. [PMID: 32863234 DOI: 10.1016/j.redox.2020.101701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
355 Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers (Basel). 2020;12. [PMID: 32899584 DOI: 10.3390/cancers12092527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Mosaad H, Emam EA, Hamed EF, El Demerdash EA, Hussein S. Vitamin D receptor gene polymorphism and hepatocellular carcinoma in chronic hepatitis C patients. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00063-7] [Reference Citation Analysis]
357 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
358 Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 12.2] [Reference Citation Analysis]
359 Niu Y, Xie W, Qin W. Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma. Acta Pharmaceutica Sinica B 2011;1:73-9. [DOI: 10.1016/j.apsb.2011.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
360 Wei PL, Hung CS, Lu HH, Batzorig U, Huang CY, Chang YJ. Areca nut extract (ANE) inhibits the progression of hepatocellular carcinoma cells via activation of ROS production and activation of autophagy. Int J Med Sci 2021;18:3452-62. [PMID: 34522171 DOI: 10.7150/ijms.61570] [Reference Citation Analysis]
361 Witzigmann D, Quagliata L, Schenk SH, Quintavalle C, Terracciano LM, Huwyler J. Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention: ASGR1 expression in liver disease. Hepatol Res 2016;46:686-96. [DOI: 10.1111/hepr.12599] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
362 Hellerbrand C, Massoumi R. Cylindromatosis-A Protective Molecule against Liver Diseases: CYLD IN LIVER DISEASE. Med Res Rev 2016;36:342-59. [DOI: 10.1002/med.21381] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
363 Abedi-Ardekani B, Gouas D, Villar S, Sotoudeh M, Hainaut P. TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations. Hepat Res Treat 2011;2011:475965. [PMID: 21869931 DOI: 10.1155/2011/475965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
364 Gan L, Liu Z, Sun C. Obesity linking to hepatocellular carcinoma: A global view. Biochim Biophys Acta Rev Cancer 2018;1869:97-102. [PMID: 29366974 DOI: 10.1016/j.bbcan.2017.12.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
365 Wang J, Zhou Y, Fei X, Chen X, Chen Y. Biostatistics mining associated method identifies AKR1B10 enhancing hepatocellular carcinoma cell growth and degenerated by miR-383-5p. Sci Rep 2018;8:11094. [PMID: 30038373 DOI: 10.1038/s41598-018-29271-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
366 Cho KJ, Choi NK, Shin MH, Chong AR. Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection. Ann Hepatobiliary Pancreat Surg. 2017;21:194-198. [PMID: 29264581 DOI: 10.14701/ahbps.2017.21.4.194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
367 Wu L, Li L, Meng S, Qi R, Mao Z, Lin M. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:365-368. [PMID: 23339388 DOI: 10.1111/jgh.12043] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
368 Wang Z, Li F, Quan Y, Shen J. Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF‑κB/COX‑2/PPAR‑γ activities. Mol Med Rep 2019;19:5417-23. [PMID: 31059053 DOI: 10.3892/mmr.2019.10198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
369 Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND, McGlynn KA. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:1808-1814. [PMID: 23197492 DOI: 10.1093/jnci/djs452] [Cited by in Crossref: 131] [Cited by in F6Publishing: 120] [Article Influence: 13.1] [Reference Citation Analysis]
370 Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, Oteo JA, Martínez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One. 2013;8:e53992. [PMID: 23326556 DOI: 10.1371/journal.pone.0053992] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
371 Addolorato G, Vassallo GA, Mirijello A, Gasbarrini A. Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. Neurotherapeutics 2020;17:127-41. [PMID: 31713188 DOI: 10.1007/s13311-019-00802-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
372 Lv S, Ning H, Li Y, Wang J, Jia Q, Wen H. Inhibition of cyclinB1 Suppressed the Proliferation, Invasion, and Epithelial Mesenchymal Transition of Hepatocellular Carcinoma Cells and Enhanced the Sensitivity to TRAIL-Induced Apoptosis. Onco Targets Ther 2020;13:1119-28. [PMID: 32103981 DOI: 10.2147/OTT.S225202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011;18:1099-1111. [PMID: 21475304 DOI: 10.1038/cdd.2011.32] [Cited by in Crossref: 164] [Cited by in F6Publishing: 154] [Article Influence: 14.9] [Reference Citation Analysis]
374 Xing H, Wang Z, Shao D, Chang Z, Ge M, Li L, Wu M, Yan Z, Dong W. Janus nanocarriers for magnetically targeted and hyperthermia-enhanced curcumin therapy of liver cancer. RSC Adv 2018;8:30448-54. [DOI: 10.1039/c8ra05694c] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
375 An J, Liu Z, Liang Q, Pan Y, Li H, Wang R, Jin Y. Overexpression of Rabl3 and Cullin7 is associated with pathogenesis and poor prognosis in hepatocellular carcinoma. Human Pathology 2017;67:146-51. [DOI: 10.1016/j.humpath.2017.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
376 Chen T, Yuan SJ, Wang J, Hu W. Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model. World J Gastroenterol 2015; 21(35): 10126-10136 [PMID: 26401077 DOI: 10.3748/wjg.v21.i35.10126] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
377 Khare S, Khare T, Ramanathan R, Ibdah JA. Hepatocellular Carcinoma: The Role of MicroRNAs. Biomolecules 2022;12:645. [DOI: 10.3390/biom12050645] [Reference Citation Analysis]
378 Muñoz-Álvarez KA, Altomonte J, Laitinen I, Ziegler S, Steiger K, Esposito I, Schmid RM, Ebert O. PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model. Mol Ther 2015;23:728-36. [PMID: 25609160 DOI: 10.1038/mt.2015.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
379 Mustafa K, Mohamed H, Shah AM, Yu S, Akhlaq M, Xiao H, Li S, Naz T, Nosheen S, Bai X, Song Y. In Vitro Anticancer Potential of Berberis lycium Royle Extracts against Human Hepatocarcinoma (HepG2) Cells. Biomed Res Int 2020;2020:8256809. [PMID: 33110920 DOI: 10.1155/2020/8256809] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
380 Ahmed Mohammed HA, Yang JD, Giama NH, Choi J, Ali HM, Mara KC, Harmsen WS, Wiesner RH, Leise MD, Therneau TM, Roberts LR. Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Liver Cancer. 2017;6:126-136. [PMID: 28275579 DOI: 10.1159/000450833] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
381 Brito AF, Ribeiro M, Abrantes AM, Mamede AC, Laranjo M, Casalta-Lopes JE, Gonçalves AC, Sarmento-Ribeiro AB, Tralhão JG, Botelho MF. New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. Nutr Cancer 2016;68:250-66. [PMID: 26943884 DOI: 10.1080/01635581.2016.1145245] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
382 Xie Z, Wang J, Liu M, Chen D, Qiu C, Sun K. CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo. PLoS One 2017;12:e0173252. [PMID: 28334043 DOI: 10.1371/journal.pone.0173252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
383 Fang S, Huang SF, Cao J, Wen YA, Zhang LP, Ren GS. Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression. Clin Exp Med. 2013;13:127-134. [PMID: 22543497 DOI: 10.1007/s10238-012-0182-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
384 Ping X, Tseng Y, Lin Y, Chiu H, Lai F, Liang J, Huang G, Yang P. A multiple measurements case-based reasoning method for predicting recurrent status of liver cancer patients. Computers in Industry 2015;69:12-21. [DOI: 10.1016/j.compind.2015.01.007] [Cited by in Crossref: 30] [Article Influence: 4.3] [Reference Citation Analysis]
385 Qiu L, Huang Y, Li Z, Dong X, Chen G, Xu H, Zeng Y, Cai Z, Liu X, Liu J. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma. Mol Oncol 2019;13:441-55. [PMID: 30537115 DOI: 10.1002/1878-0261.12424] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
386 Anwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol 2014; 20(24): 7894-7913 [PMID: 24976726 DOI: 10.3748/wjg.v20.i24.7894] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 50] [Article Influence: 6.5] [Reference Citation Analysis]
387 Panth N, Manandhar B, Paudel KR. Anticancer Activity of Punica granatum (Pomegranate): A Review: Anticancer Activity of Pomegranate. Phytother Res 2017;31:568-78. [DOI: 10.1002/ptr.5784] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
388 Kwak HW, Park JW, Koh YH, Lee JH, Yu A, Nam BH. Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area. Liver Cancer 2016;5:21-36. [PMID: 26989657 DOI: 10.1159/000367756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
389 Kotsafti A, Farinati F, Cardin R, Cillo U, Nitti D, Bortolami M. Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. BMC Gastroenterol. 2012;12:118. [PMID: 22928777 DOI: 10.1186/1471-230x-12-118] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
390 Zhang Q, Sun S, Zhu C, Zheng Y, Cai Q, Liang X, Xie H, Zhou J. Prediction and analysis of weighted genes in hepatocellular carcinoma using bioinformatics analysis. Mol Med Rep 2019;19:2479-88. [PMID: 30720105 DOI: 10.3892/mmr.2019.9929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
391 Zhou J, Yang W, Zhang S, He X, Lin J, Zhou T, Li Y, Wang G, Chen J. Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma. Cancer Manag Res 2019;11:7159-69. [PMID: 31534368 DOI: 10.2147/CMAR.S217170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
392 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 805] [Article Influence: 77.0] [Reference Citation Analysis]
393 Chen X, Pan Y, Liu H, Bai X, Wang N, Zhang B. Label-free detection of liver cancer cells by aptamer-based microcantilever biosensor. Biosens Bioelectron 2016;79:353-8. [PMID: 26735868 DOI: 10.1016/j.bios.2015.12.060] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
394 Ji Z, Li J, Wang J. Up-regulated RFC2 predicts unfavorable progression in hepatocellular carcinoma. Hereditas 2021;158:17. [PMID: 34022962 DOI: 10.1186/s41065-021-00179-9] [Reference Citation Analysis]
395 Gong B, Kao Y, Zhang C, Sun F, Zhao H. Systematic Investigation of Scutellariae Barbatae Herba for Treating Hepatocellular Carcinoma Based on Network Pharmacology. Evid Based Complement Alternat Med 2018;2018:4365739. [PMID: 30584453 DOI: 10.1155/2018/4365739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
396 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
397 Gao Y, Yin Z, Qi Y, Peng H, Ma W, Wang R, Li W. Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02462-9] [Reference Citation Analysis]
398 Tian YE, Xie XU, Lin Y, Tan G, Zhong WU. Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives. Oncol Lett 2015;9:1983-8. [PMID: 26136999 DOI: 10.3892/ol.2015.3025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
399 Ponziani F, Ojetti V, Tortora A, Di Maurizio L, Purchiaroni F, Gasbarrini A. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. Expert Opin Drug Metab Toxicol 2011;7:1535-46. [PMID: 22032293 DOI: 10.1517/17425255.2011.631911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
400 Zhang W, Chen B, Zhang Y, Li K, Hao K, Jiang L, Wang Y, Mou X, Xu X, Wang Z. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415. Biochemical and Biophysical Research Communications 2017;487:494-9. [DOI: 10.1016/j.bbrc.2017.03.156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
401 Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet. 2014;46:24-32. [PMID: 24316982 DOI: 10.1038/ng.2847] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
402 Da B, Luo S, Huang M, Song F, Ding R, Xiao Y, Fu Y, Yang Y, Wang H, Khalaf OI. Prediction of Hepatocellular Carcinoma Prognosis and Immune Cell Infiltration Using Gene Signature Associated with Inflammatory Response. Computational and Mathematical Methods in Medicine 2022;2022:1-24. [DOI: 10.1155/2022/2415129] [Reference Citation Analysis]
403 Xia YH, Lu Z, Wang SM, Hu LX. Nrf2 activation mediates tumor-specific hepatic stellate cells-induced DIgR2 expression in dendritic cells. Aging (Albany NY) 2019;11. [PMID: 31831714 DOI: 10.18632/aging.102554] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Matsuura K, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis C virus infection. J Med Virol. 2016;88:185-195. [PMID: 26211651 DOI: 10.1002/jmv.24334] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
405 Queiroz MR, Francisco Neto MJ, Garcia RG, Rahal Junior A, Salvalaggio P, Funari MB. High correlation between microbubble contrast-enhanced ultrasound, magnetic resonance and histopathology in the evaluation of hepatocellular carcinoma. Einstein (Sao Paulo) 2013;11:500-6. [PMID: 24488392 DOI: 10.1590/s1679-45082013000400017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
406 Li Q, Li W, Hui L, Zhao C, He L, Koike K. 13,28-Epoxy triterpenoid saponins from Ardisia japonica selectively inhibit proliferation of liver cancer cells without affecting normal liver cells. Bioorganic & Medicinal Chemistry Letters 2012;22:6120-5. [DOI: 10.1016/j.bmcl.2012.08.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
407 Caballeria-Casals A, Micó-Carnero M, Rojano-Alfonso C, Maroto-Serrat C, Casillas-Ramírez A, Álvarez-Mercado AI, Gracia-Sancho J, Peralta C. Role of FGF15 in Hepatic Surgery in the Presence of Tumorigenesis: Dr. Jekyll or Mr. Hyde? Cells 2021;10:1421. [PMID: 34200439 DOI: 10.3390/cells10061421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Dai W, Wang Y, Yang T, Wang J, Wu W, Gu J. Downregulation of exosomal CLEC3B in hepatocellular carcinoma promotes metastasis and angiogenesis via AMPK and VEGF signals. Cell Commun Signal 2019;17:113. [PMID: 31477130 DOI: 10.1186/s12964-019-0423-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
409 Wang N, Yu Y, Xu B, Zhang M, Li Q, Miao L. Pivotal prognostic and diagnostic role of the long non‑coding RNA colon cancer‑associated transcript 1 expression in human cancer (Review). Mol Med Rep 2019;19:771-82. [PMID: 30535444 DOI: 10.3892/mmr.2018.9721] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
410 Peng J, Li JJ, Li J, Li HW, Xu GP, Jia RR, Zhang XN, Zhao Y. Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis. Medicine (Baltimore) 2016;95:e5470. [PMID: 27902599 DOI: 10.1097/MD.0000000000005470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
411 Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol 2021;:JCO2100163. [PMID: 34185551 DOI: 10.1200/JCO.21.00163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
412 Akiel M, Rajasekaran D, Gredler R, Siddiq A, Srivastava J, Robertson C, Jariwala NH, Fisher PB, Sarkar D. Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:9-19. [PMID: 27508172 DOI: 10.2147/JHC.S44460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
413 Chen Q, Li F, Zhong C, Zou Y, Li Z, Gao Y, Zou Q, Xia Y, Wang K, Shen F. Inflammation Score System using Preoperative Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma after Hepatectomy: A Cohort Study. J Cancer 2020;11:4947-56. [PMID: 32742442 DOI: 10.7150/jca.45274] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
414 Guan YF, Huang QL, Ai YL, Chen QT, Zhao WX, Wang XM, Wu Q, Chen HZ. Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis. Oncogene 2020;39:2408-23. [PMID: 31959898 DOI: 10.1038/s41388-020-1158-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
415 Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. J Gastrointest Cancer 2020;51:584-90. [PMID: 31407252 DOI: 10.1007/s12029-019-00293-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
416 Tarocchi M, Polvani S, Marroncini G, Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol 2014; 20(33): 11630-11640 [PMID: 25206269 DOI: 10.3748/wjg.v20.i33.11630] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 87] [Article Influence: 12.6] [Reference Citation Analysis]
417 Bihari C, Rastogi A, Shasthry SM, Bajpai M, Bhadoria AS, Rajesh S, Mukund A, Kumar A, Sarin SK. Platelets contribute to growth and metastasis in hepatocellular carcinoma. APMIS. 2016;124:776-786. [PMID: 27457354 DOI: 10.1111/apm.12574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
418 Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, Li H, Zhan Q, Zhu Z. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2016;35:1575-1584. [PMID: 26073087 DOI: 10.1038/onc.2015.223] [Cited by in Crossref: 172] [Cited by in F6Publishing: 188] [Article Influence: 24.6] [Reference Citation Analysis]
419 Mahmood K, Naqvi IH, Mahmood A, Muhammad S, Muhammad N. Deal a death blow! HCC in cirrhotics - thrombotic complications: their frequency, characteristics, and risk factors. Prz Gastroenterol 2018;13:52-60. [PMID: 29657612 DOI: 10.5114/pg.2018.74566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
420 Ding SM, Lu JF, Edoo MIA, Zhou L, Xie HY, Zheng SS, Li QY. MRC-5 Cancer-associated Fibroblasts Influence Production of Cancer Stem Cell Markers and Inflammation-associated Cell Surface Molecules, in Liver Cancer Cell Lines. Int J Med Sci 2019;16:1157-70. [PMID: 31523179 DOI: 10.7150/ijms.34758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
421 Abdelaziz AO, Nabeel MM, Elbaz TM, Shousha HI, Hassan EM, Mahmoud SH, Rashed NA, Ibrahim MM, Abdelmaksoud AH. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol. 2015;50:479-484. [PMID: 25592058 DOI: 10.3109/00365521.2014.1003397] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
422 Martínez-Edo G, Fornaguera C, Borrós S, Sánchez-García D. Glycyrrhetinic Acid-Functionalized Mesoporous Silica Nanoparticles for the Co-Delivery of DOX/CPT-PEG for Targeting HepG2 Cells. Pharmaceutics 2020;12:E1048. [PMID: 33147860 DOI: 10.3390/pharmaceutics12111048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
423 Sueoka S, Kanda M, Sugimoto H, Shimizu D, Nomoto S, Oya H, Takami H, Ezaka K, Hashimoto R, Tanaka Y, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Fujiwara M, Kodera Y. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Ann Surg Oncol 2015;22:1453-60. [DOI: 10.1245/s10434-015-4524-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
424 Zhou Y, Yu Q, Qin X, Bhavsar D, Yang L, Chen Q, Zheng W, Chen L, Liu J. Improving the Anticancer Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs) via ROS-Dependent Apoptosis in SMMC-7721 Cells. ACS Appl Mater Interfaces 2016;8:15000-12. [PMID: 26018505 DOI: 10.1021/acsami.5b02261] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
425 Krause GC, Lima KG, Dias HB, da Silva EFG, Haute GV, Basso BS, Gassen RB, Marczak ES, Nunes RSB, de Oliveira JR. Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells. European Journal of Pharmacology 2017;809:32-41. [DOI: 10.1016/j.ejphar.2017.05.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
426 Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist 2021;26:e367-73. [PMID: 33140457 DOI: 10.1002/onco.13582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
427 Ge QY, Chen J, Li GX, Tan XL, Song J, Ning D, Mo J, Du PC, Liu QM, Liang HF, Ding ZY, Zhang XW, Zhang BX. GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma. Clin Transl Med 2021;11:e635. [PMID: 34841685 DOI: 10.1002/ctm2.635] [Reference Citation Analysis]
428 Zaki H, Belhassan A, Benlyas M, Lakhlifi T, Bouachrine M. New dehydroabietic acid (DHA) derivatives with anticancer activity against HepG2 cancer cell lines as a potential drug targeting EGFR kinase domain. CoMFA study and virtual ligand-based screening. J Biomol Struct Dyn 2021;39:2993-3003. [PMID: 32319344 DOI: 10.1080/07391102.2020.1759452] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
429 Chen W, Wang M, Zhang Z, Tang H, Zuo X, Meng X, Xiong M, Zhou F, Liang B, Dai F, Fang J, Gao J, Zhu J, Zhu Y, Wan H, Wang M, Chan S, Sun L. Replication the association of 2q32.2–q32.3 and 14q32.11 with hepatocellular carcinoma. Gene 2015;561:63-7. [DOI: 10.1016/j.gene.2015.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
430 Liu B, Shi Y, Peng W, Zhang Q, Liu J, Chen N, Zhu R. Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells. Mol Med Rep 2016;14:159-64. [PMID: 27176768 DOI: 10.3892/mmr.2016.5258] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
431 Thompson SM, Callstrom MR, Knudsen BE, Anderson JL, Sutor SL, Butters KA, Kuo C, Grande JP, Roberts LR, Woodrum DA. Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma. Invest Radiol 2013;48:413-21. [PMID: 23262791 DOI: 10.1097/RLI.0b013e31827a4a3f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
432 Yang J, Sun Y, Xu F, Liu W, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima T. Autophagy and glycolysis independently attenuate silibinin-induced apoptosis in human hepatocarcinoma HepG2 and Hep3B cells. Hum Exp Toxicol 2021;:9603271211017609. [PMID: 34053323 DOI: 10.1177/09603271211017609] [Reference Citation Analysis]
433 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
434 Saalim M, Resham S, Manzoor S, Ahmad H, Bangash TA, Latif A, Jaleel S. IL-22 in hepatocyte's survival of Pakistani patients with end stage liver disease: an insight into IL 22 mediated hepato-regenerative pathway. Mol Biol Rep 2019;46:1127-38. [PMID: 30603953 DOI: 10.1007/s11033-018-04573-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
435 Bharati S, Rishi P, Tripathi SK, Koul A. Changes in the electrical properties at an early stage of mouse liver carcinogenesis: Hepatic Preneoplastic Electrical Properties. Bioelectromagnetics 2013;34:429-36. [DOI: 10.1002/bem.21783] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
436 Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut Liver. 2016;10:332-339. [PMID: 27114433 DOI: 10.5009/gnl15257] [Cited by in Crossref: 225] [Cited by in F6Publishing: 255] [Article Influence: 45.0] [Reference Citation Analysis]
437 Liu M, Gu P, Guo W, Fan X. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor. Tumour Biol 2016;37:11039-48. [PMID: 26897748 DOI: 10.1007/s13277-015-4598-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
438 Chen S, Ling Q, Yu K, Huang C, Li N, Zheng J, Bao S, Cheng Q, Zhu M, Chen M. Dual oxidase 1: A predictive tool for the prognosis of hepatocellular carcinoma patients. Oncol Rep 2016;35:3198-208. [PMID: 27108801 DOI: 10.3892/or.2016.4745] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
439 Cao J, Hou P, Chen J, Wang P, Wang W, Liu W, Liu C, He X. The overexpression and prognostic role of DCAF13 in hepatocellular carcinoma. Tumour Biol 2017;39:1010428317705753. [PMID: 28631558 DOI: 10.1177/1010428317705753] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
440 Zhou Y, Fu C, Kong Y, Pan D, Wang Y, Huang S, Li Z, Ning Z, Lu X, Shan S, Xin L. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models. Anticancer Drugs 2019;30:909-16. [PMID: 30998512 DOI: 10.1097/CAD.0000000000000791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
441 Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157-167. [PMID: 26452628 DOI: 10.1136/gutjnl-2015-310514] [Cited by in Crossref: 209] [Cited by in F6Publishing: 233] [Article Influence: 29.9] [Reference Citation Analysis]
442 Xu H, Zhang S. Scutellarin-induced apoptosis in HepG2 hepatocellular carcinoma cells via a STAT3 pathway. Phytother Res 2013;27:1524-8. [PMID: 23192830 DOI: 10.1002/ptr.4892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
443 Kamimura K. Identification of molecular transition of hepatocellular carcinoma: a novel method to predict the initiation of metastasis. Stem Cell Investig 2019;6:5. [PMID: 30976602 DOI: 10.21037/sci.2019.02.02] [Reference Citation Analysis]
444 Song T, Li L, Wu S, Liu Y, Guo C, Wang W, Dai L, Zhang T, Wu H, Su B. Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. Front Oncol 2021;11:583714. [PMID: 33777736 DOI: 10.3389/fonc.2021.583714] [Reference Citation Analysis]
445 Chao X, Qian H, Wang S, Fulte S, Ding WX. Autophagy and liver cancer. Clin Mol Hepatol 2020;26:606-17. [PMID: 33053934 DOI: 10.3350/cmh.2020.0169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
446 Kumar P, Mahato DK, Kamle M, Borah R, Sharma B, Pandhi S, Tripathi V, Yadav HS, Devi S, Patil U, Xiao J, Mishra AK. Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: An overview. Phytother Res 2021. [PMID: 34237796 DOI: 10.1002/ptr.7213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Liu CQ, Xu J, Zhou ZG, Jin LL, Yu XJ, Xiao G, Lin J, Zhuang SM, Zhang YJ, Zheng L. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 2018;119:80-8. [PMID: 29921949 DOI: 10.1038/s41416-018-0144-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
448 Yang L, Zhang X, Li H, Liu J. The long noncoding RNA HOTAIR activates autophagy by upregulating ATG3 and ATG7 in hepatocellular carcinoma. Mol Biosyst. 2016;12:2605-2612. [PMID: 27301338 DOI: 10.1039/c6mb00114a] [Cited by in Crossref: 91] [Cited by in F6Publishing: 62] [Article Influence: 18.2] [Reference Citation Analysis]
449 Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J Transl Med 2012;10:245. [PMID: 23228017 DOI: 10.1186/1479-5876-10-245] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
450 Wang L, Su W, Liu Z, Zhou M, Chen S, Chen Y, Lu D, Liu Y, Fan Y, Zheng Y. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials. 2012;33:5107-5114. [PMID: 22494888 DOI: 10.1016/j.biomaterials.2012.03.067] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 10.4] [Reference Citation Analysis]
451 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 179] [Article Influence: 25.9] [Reference Citation Analysis]
452 Brito AF, Mendes M, Abrantes AM, Tralhão JG, Botelho MF. Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose. Mol Diagn Ther 2014;18:495-504. [PMID: 24852041 DOI: 10.1007/s40291-014-0106-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
453 Chen CC, Kim KH, Lau LF. The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene 2016;35:1314-23. [PMID: 26028023 DOI: 10.1038/onc.2015.190] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
454 Liu G, Huang X, Cui X, Zhang J, Wei L, Ni R, Lu C. High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Med Oncol 2013;30:537. [PMID: 23696020 DOI: 10.1007/s12032-013-0537-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
455 Yamashita T, Honda M, Kaneko S. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2011;26:960-964. [PMID: 21443660 DOI: 10.1111/j.1440-1746.2011.06723.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
456 Jayant K, Sodergren MH, Reccia I, Kusano T, Zacharoulis D, Spalding D, Pai M, Jiao LR, Huang KW. A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device Habib™-4X with the Clamp-Crush Technique. Cancers (Basel) 2018;10:E428. [PMID: 30413094 DOI: 10.3390/cancers10110428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
457 Wakasugi H, Takahashi H, Niinuma T, Kitajima H, Oikawa R, Matsumoto N, Takeba Y, Otsubo T, Takagi M, Ariizumi Y, Suzuki M, Okuse C, Iwabuchi S, Nakano M, Akutsu N, Kang JH, Matsui T, Yamada N, Sasaki H, Yamamoto E, Kai M, Sasaki Y, Sasaki S, Tanaka Y, Yotsuyanagi H, Tsutsumi T, Yamamoto H, Tokino T, Nakase H, Suzuki H, Itoh F. Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment. Cancer Lett 2018;434:91-100. [PMID: 30026054 DOI: 10.1016/j.canlet.2018.07.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
458 Li Y, Zhang Y, Zhang S, Huang D, Li B, Liang G, Wu Y, Jiang Q, Li L, Lin C, Wei Z, Meng L. circRNA circARNT2 Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting the miR-155-5p/PDK1 Axis. Mol Ther Nucleic Acids 2021;23:244-54. [PMID: 33425483 DOI: 10.1016/j.omtn.2020.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
459 Su L, Li T, Ma Y, Geng C, Huang X, Zhang X, Gao Z, Chen J. Artematrovirenolides A—D and Artematrolides S—Z, Sesquiterpenoid Dimers with Cytotoxicity against Three Hepatoma Cell Lines from Artemisia atrovirens. Chin J Chem 2022;40:104-14. [DOI: 10.1002/cjoc.202100528] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
460 Xiong Y, Hu B, Wei L, Jiang D, Zhu M. Upregulated expression of polycomb protein Ring1 contributes to poor prognosis and accelerated proliferation in human hepatocellular carcinoma. Tumour Biol 2015;36:9579-88. [PMID: 26141041 DOI: 10.1007/s13277-015-3721-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
461 Khosla R, Hemati H, Rastogi A, Ramakrishna G, Sarin SK, Trehanpati N. miR-26b-5p helps in EpCAM+cancer stem cells maintenance via HSC71/HSPA8 and augments malignant features in HCC. Liver Int. 2019;39:1692-1703. [PMID: 31276277 DOI: 10.1111/liv.14188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
462 Wang J, Tannous BA, Poznansky MC, Chen H. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. Pharmacol Res 2020;159:105010. [PMID: 32544428 DOI: 10.1016/j.phrs.2020.105010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
463 Zhang Q, Yang M, Qu Z, Zhou J, Jiang Q. Autophagy prevention sensitizes AKTi-1/2-induced anti-hepatocellular carcinoma cell activity in vitro and in vivo. Biochem Biophys Res Commun 2016;480:334-40. [PMID: 27756618 DOI: 10.1016/j.bbrc.2016.10.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
464 Li H, Wang L, Chen L, Zhao H, Cai J, Yao J, Zheng J, Yang Y, Wang G. Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio in Hepatocellular Carcinoma Patients Treated with Liver Transplantation. J Cancer 2020;11:2171-80. [PMID: 32127944 DOI: 10.7150/jca.39615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
465 Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut Liver 2016;10:939-47. [PMID: 27282264 DOI: 10.5009/gnl15527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
466 Jafri W, Kamran M. Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol 2019;9:27-33. [PMID: 31988864 DOI: 10.5005/jp-journals-10018-1292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
467 García-niño WR, Zazueta C. Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. Pharmacological Research 2015;97:84-103. [DOI: 10.1016/j.phrs.2015.04.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 95] [Article Influence: 17.6] [Reference Citation Analysis]
468 Zhu W, Doubleday PF, Butrin A, Weerawarna PM, Melani RD, Catlin DS, Dwight TA, Liu D, Kelleher NL, Silverman RB. Remarkable and Unexpected Mechanism for (S)-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase. J Am Chem Soc 2021;143:8193-207. [PMID: 34014654 DOI: 10.1021/jacs.1c03572] [Reference Citation Analysis]
469 Wu M, Yang S, Feng X, Yu F, Liu X, Dong J. Preoperative plus postoperative neutrophil-lymphocyte ratio for predicting overall survival following partial hepatectomy for hepatocellular carcinoma. Oncol Lett 2020;20:375. [PMID: 33154773 DOI: 10.3892/ol.2020.12238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
470 Gao X, Huang M, Liu L, He Y, Yu Q, Zhao H, Zhou C, Zhang J, Zhu Z, Wan J, Jiang X, Gao Y. Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations. PLoS One 2013;8:e55169. [PMID: 23359823 DOI: 10.1371/journal.pone.0055169] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
471 Nakagawa H, Fujita M, Fujimoto A. Genome sequencing analysis of liver cancer for precision medicine. Semin Cancer Biol 2019;55:120-7. [PMID: 29605648 DOI: 10.1016/j.semcancer.2018.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
472 Tian T, Wang M, Zhu W, Dai ZM, Lin S, Yang PT, Liu XH, Liu K, Zhu YY, Zheng Y, Liu M, Dai ZJ. MiR-146a and miR-196a-2 polymorphisms are associated with hepatitis virus-related hepatocellular cancer risk: a meta-analysis. Aging (Albany NY) 2017;9:381-92. [PMID: 28148887 DOI: 10.18632/aging.101160] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
473 Wang X, Yang C, Liao X, Han C, Yu T, Huang K, Yu L, Qin W, Zhu G, Su H, Liu X, Ye X, Chen B, Peng M, Peng T. NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma. Cancer Med 2017;6:2660-72. [PMID: 28960882 DOI: 10.1002/cam4.1202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
474 Atamla M, Khoury J, Dabbah I, Kramsky R, Yaacob A, Veitsman E, Saadi T. Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. Clin Exp Hepatol 2021;7:258-63. [PMID: 34712826 DOI: 10.5114/ceh.2021.109192] [Reference Citation Analysis]
475 Wang J, Zhang Y, Lu L, Lu Y, Tang Q, Pu J. Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression. J Cell Biochem 2019;120:18816-25. [PMID: 31297882 DOI: 10.1002/jcb.29197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
476 Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2012;57:3026-31. [PMID: 22585384 DOI: 10.1007/s10620-012-2212-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
477 Lv J, Xu T, Qian Z, Wang H. Association between HLA-DQ Gene Polymorphisms and HBV-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2017;2017:7150386. [PMID: 28761441 DOI: 10.1155/2017/7150386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
478 Tsuge S, Saberi B, Cheng Y, Wang Z, Kim A, Luu H, Abraham JM, Ybanez MD, Hamilton JP, Selaru FM, Villacorta-Martin C, Schlesinger F, Philosophe B, Cameron AM, Zhu Q, Anders R, Gurakar A, Meltzer SJ. Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma. Gastrointest Tumors 2019;6:11-27. [PMID: 31602373 DOI: 10.1159/000496795] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
479 Tsuei DJ, Lee PH, Peng HY, Lu HL, Su DS, Jeng YM, Hsu HC, Hsu SH, Wu JF, Ni YH, Chang MH. Male germ cell-specific RNA binding protein RBMY: a new oncogene explaining male predominance in liver cancer. PLoS One 2011;6:e26948. [PMID: 22073224 DOI: 10.1371/journal.pone.0026948] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
480 Chen YS, Hsieh PM, Lin HY, Hung CM, Lo GH, Hsu YC, Lu IC, Lee CY, Wu TC, Yeh JH, Hsiao P, Li YC, Wang YC, Hsieh KC, Lin CW. Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:220. [PMID: 33990184 DOI: 10.1186/s12876-021-01807-4] [Reference Citation Analysis]
481 Sokolowski KM, Balamurugan M, Kunnimalaiyaan S, Wilson J, Gamblin TC, Kunnimalaiyaan M. Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. Am J Surg 2016;211:755-60. [PMID: 26850133 DOI: 10.1016/j.amjsurg.2015.11.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
482 Chang ML, Lin YJ, Chang CJ, Yeh C, Chen TC, Yeh TS, Lee WC, Yeh CT. Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS One. 2013;8:e64891. [PMID: 23805180 DOI: 10.1371/journal.pone.0064891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
483 Xu F, Zha G, Wu Y, Cai W, Ao J. Overexpressing lncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-miR-93. Onco Targets Ther 2018;11:8855-63. [PMID: 30573973 DOI: 10.2147/OTT.S182005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
484 Kunadirek P, Chuaypen N, Jenjaroenpun P, Wongsurawat T, Pinjaroen N, Sirichindakul P, Nookaew I, Tangkijvanich P. Cell-Free DNA Analysis by Whole-Exome Sequencing for Hepatocellular Carcinoma: A Pilot Study in Thailand. Cancers (Basel) 2021;13:2229. [PMID: 34066484 DOI: 10.3390/cancers13092229] [Reference Citation Analysis]
485 Hidaka M, Takatsuki M, Soyama A, Tanaka T, Muraoka I, Hara T, Kuroki T, Kanematsu T, Eguchi S. Intraoperative portal venous pressure and long-term outcome after curative resection for hepatocellular carcinoma. Br J Surg. 2012;99:1284-1289. [PMID: 22864890 DOI: 10.1002/bjs.8861] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
486 Karbasforooshan H, Hayes AW, Mohammadzadeh N, Zirak MR, Karimi G. The possible role of Sirtuins and microRNAs in hepatocellular carcinoma therapy. Cell Cycle 2020;19:3209-21. [PMID: 33164623 DOI: 10.1080/15384101.2020.1843813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
487 Malik IR, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, Frelin L. A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies. Scandinavian Journal of Infectious Diseases 2011;44:55-9. [DOI: 10.3109/00365548.2011.608711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
488 Yeung BH, Shek FH, Lee NP, Wong CK. Stanniocalcin-1 Reduces Tumor Size in Human Hepatocellular Carcinoma. PLoS One 2015;10:e0139977. [PMID: 26469082 DOI: 10.1371/journal.pone.0139977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
489 Wilson JM, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. J Surg Res 2014;191:280-5. [PMID: 24996256 DOI: 10.1016/j.jss.2014.05.083] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
490 Koufaris C, Kirmizis A. Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes. Front Oncol 2021;11:691950. [PMID: 34150665 DOI: 10.3389/fonc.2021.691950] [Reference Citation Analysis]
491 Xu XF, Xing H, Han J, Li ZL, Lau WY, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Li C, Wu MC, Shen F, Yang T. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China. JAMA Surg. 2019;154:209-217. [PMID: 30422241 DOI: 10.1001/jamasurg.2018.4334] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 28.3] [Reference Citation Analysis]
492 Fu S, Li N, Zhou PC, Huang Y, Zhou RR, Fan XG. Detection of HBV DNA and antigens in HBsAg-positive patients with primary hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41:415-423. [PMID: 28286056 DOI: 10.1016/j.clinre.2017.01.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
493 Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA, Buijs M, Vali M, Geschwind JF. Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology 2012;262:834-45. [PMID: 22357885 DOI: 10.1148/radiol.11111569] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
494 Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett 2012;326:88-95. [PMID: 22863537 DOI: 10.1016/j.canlet.2012.07.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
495 Zhou X, Yang J, Wang Y, Li W, Li-Ling J, Deng Y, Zhang M. Cucurbitacin B inhibits 12-O-tetradecanoylphorbol 13-acetate-induced invasion and migration of human hepatoma cells through inactivating mitogen-activated protein kinase and PI3K/Akt signal transduction pathways. Hepatol Res. 2012;42:401-411. [PMID: 22151918 DOI: 10.1111/j.1872-034x.2011.00933.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
496 Kim SH, Cho EJ, Jang BO, Lee K, Choi JK, Choi GH, Lee JH, Yu SJ, Kim YJ, Lee YB, Yoon JH, Kim JW, Jeong SH, Jang ES. Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver Int 2021. [PMID: 34679254 DOI: 10.1111/liv.15086] [Reference Citation Analysis]
497 Lu PH, Chen MB, Liu YY, Wu MH, Li WT, Wei MX, Liu CY, Qin SK. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells. Oncotarget 2017;8:22800-10. [PMID: 28206952 DOI: 10.18632/oncotarget.15205] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
498 Yu M, Zeng M, Pan Z, Wu F, Guo L, He G. Discovery of novel akt1 inhibitor induces autophagy associated death in hepatocellular carcinoma cells. Eur J Med Chem 2020;189:112076. [PMID: 32007668 DOI: 10.1016/j.ejmech.2020.112076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
499 Lee WP, Lan KH, Li CP, Chao Y, Lin HC, Lee SD. Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma. Biochim Biophys Acta 2016;1862:837-49. [PMID: 26791804 DOI: 10.1016/j.bbadis.2015.12.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
500 Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 2013;45:72-5. [PMID: 23242368 DOI: 10.1038/ng.2483] [Cited by in Crossref: 177] [Cited by in F6Publishing: 184] [Article Influence: 17.7] [Reference Citation Analysis]
501 Yan X, Zhou H, Zhang T, Xu P, Zhang S, Huang W, Yang L, Gu X, Ni R, Zhang T. Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion. Tumour Biol 2015;36:9611-9. [PMID: 26142732 DOI: 10.1007/s13277-015-3701-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
502 Mungamuri SK, Mavuduru VA. Role of epigenetic alterations in aflatoxin‐induced hepatocellular carcinoma. Liver Cancer International 2020;1:41-50. [DOI: 10.1002/lci2.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
503 Lin M, Lv D, Zheng Y, Wu M, Xu C, Zhang Q, Wu L. Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma. Onco Targets Ther. 2018;11:3101-3110. [PMID: 29872321 DOI: 10.2147/ott.s163266] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
504 Yan XD, Yao M, Wang L, Zhang HJ, Yan MJ, Gu X, Shi Y, Chen J, Dong ZZ, Yao DF. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation. World J Gastroenterol. 2013;19:6084-6092. [PMID: 24106410 DOI: 10.3748/wjg.v19.i3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
505 Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 2013;13:52. [PMID: 23374755 DOI: 10.1186/1471-2407-13-52] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
506 Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, Yamagiwa S, Yano M, Ohkoshi S, Aoyagi Y. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett 2012;319:98-108. [PMID: 22265862 DOI: 10.1016/j.canlet.2011.12.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
507 Li L, Song X, Lv Y, Jiang Q, Fan C, Huang D. Landscape of associations between long non-coding RNAs and infiltrating immune cells in liver hepatocellular carcinoma. J Cell Mol Med 2020;24:11243-53. [PMID: 32910548 DOI: 10.1111/jcmm.15690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
508 Wu H, Pan L, Gao C, Xu H, Li Y, Zhang L, Ma L, Meng L, Sun X, Qin H. Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway. Molecules 2019;24:E1993. [PMID: 31137633 DOI: 10.3390/molecules24101993] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
509 Huang D, Guo W, Gao J, Chen J, Olatunji JO. Clinacanthus nutans (Burm. f.) Lindau Ethanol Extract Inhibits Hepatoma in Mice through Upregulation of the Immune Response. Molecules 2015;20:17405-28. [PMID: 26393569 DOI: 10.3390/molecules200917405] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
510 Li C, Zhang M, Zhang Z, Tang J, Zhang B. Microcantilever aptasensor for detecting epithelial tumor marker Mucin 1 and diagnosing human breast carcinoma MCF-7 cells. Sensors and Actuators B: Chemical 2019;297:126759. [DOI: 10.1016/j.snb.2019.126759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
511 Li G, Xu W, Zhang L, Liu T, Jin G, Song J, Wu J, Wang Y, Chen W, Zhang C, Chen X, Ding Z, Zhu P, Zhang B. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine 2019;47:128-41. [PMID: 31492561 DOI: 10.1016/j.ebiom.2019.08.064] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
512 Lee VH, Leung DK, Luk MY, Tong CC, Law MW, Ng SC, Wong KK, Poon RT, Kwong DL, Leung TW. Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. Onco Targets Ther 2015;8:3457-64. [PMID: 26640386 DOI: 10.2147/OTT.S92473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
513 Calvisi DF, Groszmann RJ, Iwakiri Y, Taddei TH. Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: A revolution in hepatocellular carcinoma prevention? Hepatology 2013;57:848-50. [DOI: 10.1002/hep.26136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
514 Zhu X, Zhang J, Fan W, Wang F, Yao H, Wang Z, Hou S, Tian Y, Fu W, Xie D. The rs391957 variant cis-regulating oncogene GRP78 expression contributes to the risk of hepatocellular carcinoma. Carcinogenesis. 2013;34:1273-1280. [PMID: 23416888 DOI: 10.1093/carcin/bgt061] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
515 Liu Y, Li H, Dong J, Ma L, Liao A, Rong Z, Zhou Z, Cao L, Wang F, Wang J, Wang A. mTOR and ERK regulate VKORC1 expression in both hepatoma cells and hepatocytes which influence blood coagulation. Clin Exp Med 2019;19:121-32. [PMID: 30306378 DOI: 10.1007/s10238-018-0528-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
516 Chang IC, Huang SF, Chen PJ, Chen CL, Chen CL, Wu CC, Tsai CC, Lee PH, Chen MF, Lee CM, Yu HC, Lo GH, Yeh CT, Hong CC, Eng HL, Wang J, Tseng HH, Hsiao CH, Wu HI, Yen TC, Liaw YF. The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network. Medicine (Baltimore) 2016;95:e3284. [PMID: 27082566 DOI: 10.1097/MD.0000000000003284] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
517 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
518 Zhang J, Wang C, Chen M, Cao J, Zhong Y, Chen L, Shen HM, Xia D. Epigenetic silencing of glutaminase 2 in human liver and colon cancers. BMC Cancer 2013;13:601. [PMID: 24330717 DOI: 10.1186/1471-2407-13-601] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
519 Xing T, Yan T, Zhou Q. Identification of key candidate genes and pathways in hepatocellular carcinoma by integrated bioinformatical analysis. Exp Ther Med 2018;15:4932-42. [PMID: 29805517 DOI: 10.3892/etm.2018.6075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
520 Ma W, Wong CC, Tung EK, Wong CM, Ng IO. RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-Kinase/Myosin phosphatase target pathway. Hepatology 2013;57:152-61. [DOI: 10.1002/hep.25987] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
521 Xu Z, Zhai L, Yi T, Gao H, Fan F, Li Y, Wang Y, Li N, Xing X, Su N, Wu F, Chang L, Chen X, Dai E, Zhao C, Yang X, Cui C, Xu P. Hepatitis B virus X induces inflammation and cancer in mice liver through dysregulation of cytoskeletal remodeling and lipid metabolism. Oncotarget 2016;7:70559-74. [PMID: 27708241 DOI: 10.18632/oncotarget.12372] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
522 Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One 2018;13:e0207132. [PMID: 30408106 DOI: 10.1371/journal.pone.0207132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
523 Gull N, Arshad F, Naikoo GA, Hassan IU, Pedram MZ, Ahmad A, Aljabali AAA, Mishra V, Satija S, Charbe N, Negi P, Goyal R, Serrano-Aroca Á, Al Zoubi MS, El-Tanani M, Tambuwala MM. Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma. J Gastrointest Cancer 2022. [PMID: 35285010 DOI: 10.1007/s12029-022-00809-z] [Reference Citation Analysis]
524 Ciurea AM, Vere CC, Schenker M, Gheonea IA, Streba L, Săndulescu LD, Mehedinţeanu AM, Gheonea DI. Evaluation of Hepatocellular Carcinoma Patients: Interim Analysis of Cases from a Tertiary Referral Center in Craiova, Romania. Curr Health Sci J 2021;47:10-5. [PMID: 34211741 DOI: 10.12865/CHSJ.47.01.02] [Reference Citation Analysis]
525 Xia C, Shui L, Lou G, Ye B, Zhu W, Wang J, Wu S, Xu X, Mao L, Xu W, Chen Z, Liu Y, Zheng M. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop. Sci Rep 2017;7:4396. [PMID: 28667294 DOI: 10.1038/s41598-017-04487-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
526 Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5:181006. [PMID: 30662724 DOI: 10.1098/rsos.181006] [Cited by in Crossref: 124] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
527 Umeda S, Kanda M, Sugimoto H, Tanaka H, Hayashi M, Yamada S, Fujii T, Takami H, Niwa Y, Iwata N, Tanaka C, Kobayashi D, Fujiwara M, Kodera Y. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer 2017;17:610. [PMID: 28863781 DOI: 10.1186/s12885-017-3629-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
528 Li W, Li Y, Siraj S, Jin H, Fan Y, Yang X, Huang X, Wang X, Wang J, Liu L, Du L, Chen Q. FUN14 Domain-Containing 1-Mediated Mitophagy Suppresses Hepatocarcinogenesis by Inhibition of Inflammasome Activation in Mice. Hepatology. 2019;69:604-621. [PMID: 30053328 DOI: 10.1002/hep.30191] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 16.7] [Reference Citation Analysis]
529 Bhullar KS, Jha A, Rupasinghe HP. Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact 2015;242:107-22. [PMID: 26409325 DOI: 10.1016/j.cbi.2015.09.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
530 Fu Y, Zhao H, Li X, Kang H, Ma J, Yao F, Du N. Expression of HSPA2 in human hepatocellular carcinoma and its clinical significance. Tumor Biol 2014;35:11283-7. [DOI: 10.1007/s13277-014-2430-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
531 Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47:1278-1287. [PMID: 29516535 DOI: 10.1111/apt.14593] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
532 Grise F, Sena S, Bidaud-meynard A, Baud J, Hiriart J, Makki K, Dugot-senant N, Staedel C, Bioulac-sage P, Zucman-rossi J, Rosenbaum J, Moreau V. Rnd3/RhoE Is down-regulated in hepatocellular carcinoma and controls cellular invasion. Hepatology 2012;55:1766-75. [DOI: 10.1002/hep.25568] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
533 Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L, Shen LM. Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation. Cancer Cell Int. 2014;14:49. [PMID: 24991192 DOI: 10.1186/1475-2867-14-49] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
534 Li J, Liu K, Sheng Y, Zhang Q, Chen L, Qian H, Wu H, Su C. Enrichment and identification of differentially expressed genes in hepatocellular carcinoma stem-like cells. Oncol Lett 2020;20:299. [PMID: 33101493 DOI: 10.3892/ol.2020.12162] [Reference Citation Analysis]
535 Santhekadur PK, Kumar DP. RISC assembly and post-transcriptional gene regulation in Hepatocellular Carcinoma. Genes Dis 2020;7:199-204. [PMID: 32215289 DOI: 10.1016/j.gendis.2019.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
536 Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, Wu W, Sai WL, Yang JL, Zhang HJ. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2011;10:289-294. [PMID: 21669573 DOI: 10.1016/s1499-3872(11)60048-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
537 Mir IH, Jyothi KC, Thirunavukkarasu C. The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation. J Cell Biochem 2021. [PMID: 34897788 DOI: 10.1002/jcb.30190] [Reference Citation Analysis]
538 Mukaide M, Sugiyama M, Korenaga M, Murata K, Kanto T, Masaki N, Mizokami M. High-throughput and sensitive next-generation droplet digital PCR assay for the quantitation of the hepatitis C virus mutation at core amino acid 70. J Virol Methods. 2014;207:169-177. [PMID: 25019167 DOI: 10.1016/j.jviromet.2014.07.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
539 Zhu KT, Wu ZR, Lu XF, Ji HJ, Zhou YJ, Cao XY, Zhu YJ, Bu H, Shi YJ. Clinical significance of expression of histone deacetylase 3 in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2017; 25(10): 922-928 [DOI: 10.11569/wcjd.v25.i10.922] [Reference Citation Analysis]
540 Sarvari J, Mojtahedi Z, Kuramitsu Y, Malek-Hosseini SA, Shamsi Shahrabadi M, Ghaderi A, Nakamura K. Differential expression of haptoglobin isoforms in chronic active hepatitis, cirrhosis and HCC related to HBV infection. Oncol Lett 2011;2:871-7. [PMID: 22866143 DOI: 10.3892/ol.2011.321] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
541 Shi L, Peng F, Tao Y, Fan X, Li N. Roles of long noncoding RNAs in hepatocellular carcinoma. Virus Res. 2016;223:131-139. [PMID: 27374059 DOI: 10.1016/j.virusres.2016.06.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
542 Sun JX, Shi J, Li N, Guo WX, Wu MC, Lau WY, Cheng SQ. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med 2016;13:452-8. [PMID: 28154776 DOI: 10.20892/j.issn.2095-3941.2016.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
543 Jeon TW, Yang H, Lee CG, Oh ST, Seo D, Baik IH, Lee EH, Yun I, Park KR, Lee YH. Electro-hyperthermia up-regulates tumour suppressor Septin 4 to induce apoptotic cell death in hepatocellular carcinoma. Int J Hyperthermia 2016;32:648-56. [PMID: 27269053 DOI: 10.1080/02656736.2016.1186290] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
544 Zhang X, Li M, Xi H, Zhang R, Chen J, Zhang Y, Xu X. Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing. Oncotarget. 2016;7:70264-70275. [PMID: 27602500 DOI: 10.18632/oncotarget.11840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
545 Wang Q, Tian X, Zhang C, Wang Q. Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol 2012;29:2727-36. [DOI: 10.1007/s12032-011-0106-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
546 Gulzar N, Dingerdissen H, Yan C, Mazumder R. Impact of Nonsynonymous Single-Nucleotide Variations on Post-Translational Modification Sites in Human Proteins. Methods Mol Biol 2017;1558:159-90. [PMID: 28150238 DOI: 10.1007/978-1-4939-6783-4_8] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
547 Singh H, Lim J, Sharma A, Yoon DW, Kim JH, Yang Z, Qu J, Kim J, Lee SG, Kim JS. A pH‐Responsive Glycyrrhetinic‐Acid‐Modified Small‐Molecule Conjugate for NIR Imaging of Hepatocellular Carcinoma (HCC). ChemBioChem 2018;20:614-20. [DOI: 10.1002/cbic.201800619] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
548 Wang PS, Kuai J, Li H, Wang CG, Shi BJ, Zhong L. Mannose-binding lectin 2 rs11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population. Hepatobiliary Pancreat Dis Int 2016;15:282-8. [PMID: 27298104 DOI: 10.1016/s1499-3872(16)60050-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
549 Marchio A, Bertani S, Rojas Rojas T, Doimi F, Terris B, Deharo E, Dejean A, Ruiz E, Pineau P. A peculiar mutation spectrum emerging from young peruvian patients with hepatocellular carcinoma. PLoS One 2014;9:e114912. [PMID: 25502816 DOI: 10.1371/journal.pone.0114912] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
550 Chuang TY, Wu HL, Min J, Diamond M, Azziz R, Chen YH. Berberine regulates the protein expression of multiple tumorigenesis-related genes in hepatocellular carcinoma cell lines. Cancer Cell Int 2017;17:59. [PMID: 28572744 DOI: 10.1186/s12935-017-0429-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
551 Yu Q, Zhou C, Wang J, Chen L, Zheng S, Zhang J. A functional insertion/deletion polymorphism in the promoter of PDCD6IP is associated with the susceptibility of hepatocellular carcinoma in a Chinese population. DNA Cell Biol 2013;32:451-7. [PMID: 23777424 DOI: 10.1089/dna.2013.2061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
552 Bertani S, Pineau P, Loli S, Moura J, Zimic M, Deharo E, Ruiz E. An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations. PLoS One 2013;8:e67756. [PMID: 23840771 DOI: 10.1371/journal.pone.0067756] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
553 Ali N, Chandrakesan P, Nguyen CB, Husain S, Gillaspy AF, Huycke M, Berry WL, May R, Qu D, Weygant N, Sureban SM, Bronze MS, Dhanasekaran DN, Houchen CW. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget 2015;6:20327-44. [PMID: 25948779 DOI: 10.18632/oncotarget.3972] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
554 Shi H, Huttad LV, Tan M, Liu H, Chua M, Cheng Z, So S. NIR-II imaging of hepatocellular carcinoma based on a humanized anti-GPC3 antibody. RSC Med Chem 2022;13:90-7. [DOI: 10.1039/d1md00313e] [Reference Citation Analysis]
555 Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 2018;67:1845-54. [PMID: 29602780 DOI: 10.1136/gutjnl-2017-315201] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 13.5] [Reference Citation Analysis]
556 Sakr MA, Al-azzawi MA, Anis A, Abd El-aziz AA, Ebeid ME, Shokeer MA, fayed A. The correlation between P53 and COX-2 expression and the pathological alteration in hepatocellular carcinoma. Egypt J Med Hum Genet 2022;23. [DOI: 10.1186/s43042-022-00230-y] [Reference Citation Analysis]
557 Cao Q, Lu W, Zhou T, Liu Y, Cai X, Zhu J, Cao P. Analgesic-antitumor peptide inhibits angiogenesis by suppressing AKT activation in hepatocellular carcinoma. Mol Cell Biochem 2019;455:119-25. [PMID: 30535530 DOI: 10.1007/s11010-018-3475-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
558 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
559 Liu WB, Jia WD, Ma JL, Xu GL, Zhou HC, Peng Y, Wang W. Knockdown of GTPBP4 inhibits cell growth and survival in human hepatocellular carcinoma and its prognostic significance. Oncotarget 2017;8:93984-97. [PMID: 29212203 DOI: 10.18632/oncotarget.21500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
560 Qiu YQ, Zhou J, Kang XS, Ding LM, Yu W, Tan FL, Deng DF. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model. Sci Rep 2014;4:4324. [PMID: 24632756 DOI: 10.1038/srep04324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
561 Zhang H, Chu K, Zheng C, Ren L, Tian R. Pseudogene DUXAP8 Promotes Cell Proliferation and Migration of Hepatocellular Carcinoma by Sponging MiR-490-5p to Induce BUB1 Expression. Front Genet 2020;11:666. [PMID: 32849765 DOI: 10.3389/fgene.2020.00666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
562 Wang L, Li N, Fan X, Wang X, Zhang X, Zhang K, Han Q, Lv Y, Liu Z. Circulating CTLA-4 levels and CTLA4 polymorphisms associate with disease condition and progression and hepatocellular carcinoma patients' survival in chronic hepatitis B virus infection. Int Immunopharmacol 2020;82:106377. [PMID: 32163858 DOI: 10.1016/j.intimp.2020.106377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
563 Page AJ, Cosgrove D, Pawlik TM. Comparative effectiveness in hepatic malignancies. Cancer Treat Res 2015;164:195-219. [PMID: 25677025 DOI: 10.1007/978-3-319-12553-4_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
564 Li Q, Gu X, Weng H, Ghafoory S, Liu Y, Feng T, Dzieran J, Li L, Ilkavets I, Kruithof-de Julio M, Munker S, Marx A, Piiper A, Augusto Alonso E, Gretz N, Gao C, Wölfl S, Dooley S, Breitkopf-Heinlein K. Bone morphogenetic protein-9 induces epithelial to mesenchymal transition in hepatocellular carcinoma cells. Cancer Sci 2013;104:398-408. [PMID: 23281849 DOI: 10.1111/cas.12093] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
565 Aboulnasr F, Hazari S, Nayak S, Chandra PK, Panigrahi R, Ferraris P, Chava S, Kurt R, Song K, Dash A, Balart LA, Garry RF, Wu T, Dash S. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System. PLoS One 2015;10:e0141655. [PMID: 26657215 DOI: 10.1371/journal.pone.0141655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
566 Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol 2013; 19(2): 284-289 [PMID: 23345952 DOI: 10.3748/wjg.v19.i2.284] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
567 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
568 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
569 Arai J, Goto K, Otoyama Y, Nakajima Y, Sugiura I, Kajiwara A, Tojo M, Ichikawa Y, Uozumi S, Shimozuma Y, Uchikoshi M, Sakaki M, Nozawa H, Nakagawa R, Muroyama R, Kato N, Yoshida H. Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Cancer Immunol Immunother 2021;70:203-13. [PMID: 32683508 DOI: 10.1007/s00262-020-02660-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
570 Wang C, Zhao H, Zhao X, Wan J, Wang D, Bi W, Jiang X, Gao Y. Association between an insertion/deletion polymorphism within 3'UTR of SGSM3 and risk of hepatocellular carcinoma. Tumour Biol 2014;35:295-301. [PMID: 23918301 DOI: 10.1007/s13277-013-1039-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
571 Ramalho LNZ, Porta LD, Rosim RE, Petta T, Augusto MJ, Silva DM, Ramalho FS, Oliveira CAF. Aflatoxin B1 residues in human livers and their relationship with markers of hepatic carcinogenesis in São Paulo, Brazil. Toxicol Rep 2018;5:777-84. [PMID: 30101081 DOI: 10.1016/j.toxrep.2018.07.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
572 Liang DY, Huang W, Chang Q, Hou YQ. ShDcR3 sensitizes TRAIL-resistant HCC cells by inducing caspase-dependent apoptosis while suppressing NF-κB dependent cFLIPL expression. PLoS One 2018;13:e0191545. [PMID: 29444104 DOI: 10.1371/journal.pone.0191545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
573 Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T, Umar S, Anant S, Houchen CW. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol. 2011;85:12292-12303. [PMID: 21937640 DOI: 10.1128/jvi.05920-11] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
574 Wu Z, Sun Y, Huang Y, Zhu S, Feng Y, Ye H, Liu C, Tang S. Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population. Oncotarget 2016;7:77968-77. [PMID: 27792999 DOI: 10.18632/oncotarget.12864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
575 Shao D, Li J, Pan Y, Zhang X, Zheng X, Wang Z, Zhang M, Zhang H, Chen L. Noninvasive theranostic imaging of HSV-TK/GCV suicide gene therapy in liver cancer by folate-targeted quantum dot-based liposomes. Biomater Sci 2015;3:833-41. [DOI: 10.1039/c5bm00077g] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
576 Singh H, Kim SJ, Kang DH, Kim H, Sharma A, Kim WY, Kang C, Kim JS. Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity. Chem Commun 2018;54:12353-6. [DOI: 10.1039/c8cc05175e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
577 Chen F, Li Y, Feng Y, He X, Wang L. Evaluation of Antimetastatic Effect of lncRNA-ATB siRNA Delivered Using Ultrasound-Targeted Microbubble Destruction. DNA Cell Biol 2016;35:393-7. [PMID: 27027475 DOI: 10.1089/dna.2016.3254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
578 Ma X, Yu G, Chen X, Xiao Q, Shi Z, Zhang L, Chen H, Zhang P, Ding D, Huang H, Saiyin H, Chen T, Lu P, Wang N, Yu H, Conran C, Sun J, Zheng SL, Xu J, Yu L, Jiang D. MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma. Tumor Biol 2016;37:9931-42. [DOI: 10.1007/s13277-016-4897-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
579 Wang Z, Han W, Sui X, Fang Y, Pan H. Autophagy: A novel therapeutic target for hepatocarcinoma (Review). Oncol Lett. 2014;7:1345-1351. [PMID: 24765136 DOI: 10.3892/ol.2014.1916] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
580 Shimizu D, Kanda M, Sugimoto H, Sueoka S, Takami H, Ezaka K, Tanaka Y, Hashimoto R, Okamura Y, Iwata N, Tanaka C, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncol Lett 2016;11:1847-54. [PMID: 26998088 DOI: 10.3892/ol.2016.4120] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
581 Ding M, Li J, Yu Y, Liu H, Yan Z, Wang J, Qian Q. Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells. J Transl Med 2015;13:259. [PMID: 26259570 DOI: 10.1186/s12967-015-0609-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
582 Thompson SM, Jondal DE, Butters KA, Knudsen BE, Anderson JL, Stokes MP, Jia X, Grande JP, Roberts LR, Callstrom MR, Woodrum DA. Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma. Int J Hyperthermia 2018;34:812-23. [PMID: 28954551 DOI: 10.1080/02656736.2017.1385859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
583 Huang K, Liao X, Han C, Wang X, Yu T, Yang C, Liu X, Yu L, Chen Z, Qin W, Zhu G, Su H, Liu Z, Zeng X, Zhou X, Lu S, Huang J, Liang Y, Liu Z, Deng J, Ye X, Peng T. Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. J Cancer 2019;10:1453-65. [PMID: 31031855 DOI: 10.7150/jca.28919] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
584 Zhang Y, Wang Y, Du Z, Wang Q, Wu M, Wang X, Wang L, Cao L, Hamid AS, Zhang G. Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation. Onco Targets Ther. 2012;5:143-152. [PMID: 22927763 DOI: 10.2147/ott.s32918] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
585 Huang G, Yang J, Chen L, Wu T. Editorial: Applications of Metagenomics in Studying Human Cancer. Front Genet 2021;12:760141. [PMID: 34603403 DOI: 10.3389/fgene.2021.760141] [Reference Citation Analysis]
586 Shibata T, Arai Y, Totoki Y. Molecular genomic landscapes of hepatobiliary cancer. Cancer Sci 2018;109:1282-91. [PMID: 29573058 DOI: 10.1111/cas.13582] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
587 Yang JD, Ahmed Mohammed H, Harmsen WS, Enders F, Gores GJ, Roberts LR. Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study. J Clin Gastroenterol 2017;51:742-8. [PMID: 28445235 DOI: 10.1097/MCG.0000000000000810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
588 Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261-272. [PMID: 25270965 DOI: 10.1007/s00535-014-1000-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
589 Sarma M, Padma S, Pavithran P, Somasundaram VH, Sundaram PS. Extrahepatic metastases of hepatocellular carcinoma on 18F FDG PET CT. J Egypt Natl Canc Inst 2021;33:36. [PMID: 34825288 DOI: 10.1186/s43046-021-00086-0] [Reference Citation Analysis]
590 Tang Y, Zhan L, Lu Y, Chen H, Qin S, Liang Z, Li H, Wei W, Li S, Qin X. Association of LEPR gene polymorphisms with the risk of hepatitis B virus-related liver disease in Guangxi Chinese: A case-control study. Infect Genet Evol 2020;84:104366. [PMID: 32428570 DOI: 10.1016/j.meegid.2020.104366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
591 Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021. [PMID: 34355489 DOI: 10.1002/lt.26257] [Reference Citation Analysis]
592 Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H, Nam SW. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One. 2012;7:e34265. [PMID: 22496786 DOI: 10.1371/journal.pone.0034265] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 6.7] [Reference Citation Analysis]
593 Wang J, Han K, Zhang C, Chen X, Li Y, Zhu L, Luo T. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients. Biosci Rep 2021;41:BSR20210583. [PMID: 33988674 DOI: 10.1042/BSR20210583] [Reference Citation Analysis]
594 Zhu C, Zhao M, Fan L, Cao X, Xia Q, Zhou J, Yin H, Zhao L. Chitopentaose inhibits hepatocellular carcinoma by inducing mitochondrial mediated apoptosis and suppressing protective autophagy. Bioresour Bioprocess 2021;8. [DOI: 10.1186/s40643-020-00358-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Yang JD, Mohamed EA, Aziz AO, Shousha HI, Hashem MB, Nabeel MM, Abdelmaksoud AH, Elbaz TM, Afihene MY, Duduyemi BM, Ayawin JP, Gyedu A, Lohouès-Kouacou MJ, Ndam AW, Moustafa EF, Hassany SM, Moussa AM, Ugiagbe RA, Omuemu CE, Anthony R, Palmer D, Nyanga AF, Malu AO, Obekpa S, Abdo AE, Siddig AI, Mudawi HM, Okonkwo U, Kooffreh-Ada M, Awuku YA, Nartey YA, Abbew ET, Awuku NA, Otegbayo JA, Akande KO, Desalegn HM, Omonisi AE, Ajayi AO, Okeke EN, Duguru MJ, Davwar PM, Okorie MC, Mustapha S, Debes JD, Ocama P, Lesi OA, Odeghe E, Bello R, Onyekwere C, Ekere F, Igetei R, Mah'moud MA, Addissie B, Ali HM, Gores GJ, Topazian MD, Roberts LR; Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2017;2:103-11. [PMID: 28403980 DOI: 10.1016/S2468-1253(16)30161-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
596 Qadir XV, Han C, Lu D, Zhang J, Wu T. miR-185 inhibits hepatocellular carcinoma growth by targeting the DNMT1/PTEN/Akt pathway. Am J Pathol. 2014;184:2355-2364. [PMID: 24911372 DOI: 10.1016/j.ajpath.2014.05.004] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 8.4] [Reference Citation Analysis]
597 Wani NA, Zhang B, Teng KY, Barajas JM, Motiwala T, Hu P, Yu L, Brüschweiler R, Ghoshal K, Jacob ST. Reprograming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis. Mol Cancer Res 2018;16:256-68. [PMID: 29187559 DOI: 10.1158/1541-7786.MCR-17-0304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
598 Wang Y, Jiang J, Li Q, Ma H, Xu Z, Gao Y. KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance. Int J Clin Oncol 2016;21:927-33. [PMID: 27095111 DOI: 10.1007/s10147-016-0979-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
599 Wang Z, Shao D, Chang Z, Lu M, Wang Y, Yue J, Yang D, Li M, Xu Q, Dong W. Janus Gold Nanoplatform for Synergetic Chemoradiotherapy and Computed Tomography Imaging of Hepatocellular Carcinoma. ACS Nano 2017;11:12732-41. [DOI: 10.1021/acsnano.7b07486] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 17.2] [Reference Citation Analysis]
600 Zhou Z, Deng H, Yan W, Luo M, Tu W, Xia Y, He J, Han P, Fu Y, Tian D. AEG-1 promotes anoikis resistance and orientation chemotaxis in hepatocellular carcinoma cells. PLoS One. 2014;9:e100372. [PMID: 24941119 DOI: 10.1371/journal.pone.0100372] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
601 Liu W, Xu C, Meng Q, Kang P. The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101527. [PMID: 33713978 DOI: 10.1016/j.clinre.2020.08.005] [Reference Citation Analysis]
602 Ji X, Zhang Q, Du Y, Liu W, Li Z, Hou X, Cao G. Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma. Curr Genomics. 2014;15:469-480. [PMID: 25646075 DOI: 10.2174/1389202915666141114213833] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
603 Lee C, Chen W, Lin C, Teng W, Lin S, Chiu C. Radiofrequency ablation assisted by real-time virtual sonography for hepatocellular carcinoma inconspicuous under sonography and high-risk locations. The Kaohsiung Journal of Medical Sciences 2015;31:413-9. [DOI: 10.1016/j.kjms.2015.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
604 Feiks A, Nowotny C, Gruber W. [Characteristics of peripheral rheograms following thermal provocation in normal and pathologic pregnancy]. Geburtshilfe Frauenheilkd 1988;48:647-50. [PMID: 3181714 DOI: 10.1055/s-2008-1026557] [Reference Citation Analysis]
605 Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, Zhong Z, Zhang F, Tang R. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol. 2014;35:7407-7413. [PMID: 24777334 DOI: 10.1007/s13277-014-1976-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
606 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
607 Girgis AS, Panda SS, Farag IS, El-Shabiny AM, Moustafa AM, Ismail NS, Pillai GG, Panda CS, Hall CD, Katritzky AR. Synthesis, and QSAR analysis of anti-oncological active spiro-alkaloids. Org Biomol Chem 2015;13:1741-53. [PMID: 25502495 DOI: 10.1039/c4ob02149e] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 2.9] [Reference Citation Analysis]
608 Du X, Lin W, Su H. Highly efficient polyethylene glycol‐functionalised gold nanorods for photothermal ablation of hepatocellular carcinoma cells. IET nanobiotechnol 2019;13:842-9. [DOI: 10.1049/iet-nbt.2018.5417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
609 Fan Y, Lu H, Ma H, Feng F, Hu X, Zhang Q, Wang J, Xu Y, Zhao Q. Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition. Food Funct 2015;6:3746-59. [PMID: 26369427 DOI: 10.1039/c5fo00371g] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
610 Zhu S, Cao S, Yang W, Che J, Li D, Pei R, Ding Y. The Maturation of Tumor Suppressor miR-497 in Hepatocellular Carcinoma is Inhibited by Oncogenic circRNA SCARB1. Cancer Manag Res 2021;13:5751-9. [PMID: 34305409 DOI: 10.2147/CMAR.S304125] [Reference Citation Analysis]
611 Xu D, Liu X, Wu J, Wang Y, Zhou K, Chen W, Chen J, Chen C, Chen L. LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX. Cancer Biol Ther 2020;21:927-36. [PMID: 32931356 DOI: 10.1080/15384047.2020.1806689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
612 Qian H, Chao X, Williams J, Fulte S, Li T, Yang L, Ding WX. Autophagy in liver diseases: A review. Mol Aspects Med 2021;:100973. [PMID: 34120768 DOI: 10.1016/j.mam.2021.100973] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
613 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
614 Chen M, Huang H, Pan Y, Li Z, Ouyang S, Ren C, Zhao Q. Preparation of layering-structured magnetic fluorescent liposomes and labeling of HepG2 cells. Biomed Mater Eng 2022. [PMID: 35180107 DOI: 10.3233/BME-228000] [Reference Citation Analysis]
615 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
616 Solorio L, Wu H, Hernandez C, Gangolli M, Exner AA. Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model. Ther Deliv 2016;7:201-12. [PMID: 27010983 DOI: 10.4155/tde-2015-0008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
617 Qiu Z, Zhang C, Zhou J, Hu J, Sheng L, Li X, Chen L, Li X, Deng X, Zheng G. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. Mol Carcinog 2019;58:31-41. [PMID: 30182439 DOI: 10.1002/mc.22904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
618 Tian Y, Lee Y, Kim H, Kang HW. In vitro anti-tumor effect of low-power laser irradiation (LPLI) on gastroenterological carcinoma cells. Lasers Med Sci 2020;35:677-85. [DOI: 10.1007/s10103-019-02869-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
619 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
620 Yuan L, Dong L, Yu G, Fan W, Zhang L, Wang P, Hu X, Zhao M. Aberrant expression of B7‑H4 may contribute to the development of hepatocellular carcinoma. Mol Med Rep 2016;14:5015-24. [PMID: 27840912 DOI: 10.3892/mmr.2016.5887] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
621 Cho EJ, Kwack MS, Jang ES, You SJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011;84 Suppl 1:17-22. [PMID: 22156481 DOI: 10.1159/000333210] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
622 Delgado ER, Yang J, So J, Leimgruber S, Kahn M, Ishitani T, Shin D, Mustata Wilson G, Monga SP. Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling. Am J Pathol 2014;184:2111-22. [PMID: 24819961 DOI: 10.1016/j.ajpath.2014.04.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
623 Wang SJ, Chao D, Wei W, Nan G, Li JY, Liu FL, Li L, Jiang JL, Cui HY, Chen ZN. CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:145. [PMID: 32727598 DOI: 10.1186/s13046-020-01647-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
624 Shu G, Mi X, Cai J, Zhang X, Yin W, Yang X, Li Y, Chen L, Deng X. Brucine, an alkaloid from seeds of Strychnos nux-vomica Linn., represses hepatocellular carcinoma cell migration and metastasis: the role of hypoxia inducible factor 1 pathway. Toxicol Lett 2013;222:91-101. [PMID: 23933019 DOI: 10.1016/j.toxlet.2013.07.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
625 Wang XB, Chen J, Xiang BD, Wu FX, Li LQ. High CONUT score predicts poor survival and postoperative HBV reactivation in HBV-related hepatocellular carcinoma patients with low HBV-DNA levels. Eur J Surg Oncol 2019;45:782-7. [PMID: 30503048 DOI: 10.1016/j.ejso.2018.11.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
626 Park IW, Fan Y, Luo X, Ryou MG, Liu J, Green L, He JJ. HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication. PLoS One 2014;9:e99545. [PMID: 24911518 DOI: 10.1371/journal.pone.0099545] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
627 Kasprzak A, Adamek A, Przybyszewska W, Pyda P, Szmeja J, Seraszek-Jaros A, Lanzafame A, Surdacka A, Mozer-Lisewska I, Koczorowska M. Insulin-like growth factor-1 mRNA isoforms and insulin-like growth factor-1 receptor mRNA expression in chronic hepatitis C. World J Gastroenterol 2015; 21(13): 3867-3875 [PMID: 25852271 DOI: 10.3748/wjg.v21.i13.3867] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
628 Liang JD, Ping XO, Tseng YJ, Huang GT, Lai F, Yang PM. Recurrence predictive models for patients with hepatocellular carcinoma after radiofrequency ablation using support vector machines with feature selection methods. Comput Methods Programs Biomed. 2014;117:425-434. [PMID: 25278224 DOI: 10.1016/j.cmpb.2014.09.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
629 Xue M, Zhou C, Zheng Y, Zhang Z, Wang S, Fu Y, Atyah M, Xue X, Zhu L, Dong Q, Jia H, Ren N, Hu R. The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. Aging (Albany NY) 2020;12:15566-80. [PMID: 32756012 DOI: 10.18632/aging.103592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
630 Yang D, Yao M, Yan Y, Liu Y, Wen X, Chen X, Lu F. Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease. Biomolecules 2021;11:205. [PMID: 33540642 DOI: 10.3390/biom11020205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
631 Gao L, Wang KX, Zhou YZ, Fang JS, Qin XM, Du GH. Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation. Sci Rep 2018;8:624. [PMID: 29330507 DOI: 10.1038/s41598-017-18325-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 15.0] [Reference Citation Analysis]
632 Xu Q, Kobayashi S, Ye X, Meng X. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. Sci Rep. 2014;4:7252. [PMID: 25429732 DOI: 10.1038/srep07252] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 6.4] [Reference Citation Analysis]
633 Abdlaty R, Abbass MA, Awadallah AM. Radiofrequency Ablation for Liver: Comparison between Expert Eye and Hyperspectral Imaging Assessment. Photodiagnosis Photodyn Ther 2021;:102699. [PMID: 34942401 DOI: 10.1016/j.pdpdt.2021.102699] [Reference Citation Analysis]
634 Gao A, Ke Z, Wang J, Yang J, Chen S, Chen H. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 2013;34:1806-14. [DOI: 10.1093/carcin/bgt108] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 11.0] [Reference Citation Analysis]
635 Liu H, Gao Y, Hu S, Fan Z, Wang X, Li S. Bioinformatics Analysis of Differentially Expressed Rhythm Genes in Liver Hepatocellular Carcinoma. Front Genet 2021;12:680528. [PMID: 34149816 DOI: 10.3389/fgene.2021.680528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
636 Liu Y, Wang Z, Cao Y, Zhang G, Chen W, Jiang C. Preoperative inflammation-based markers predict early and late recurrence of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary & Pancreatic Diseases International 2016;15:266-74. [DOI: 10.1016/s1499-3872(16)60094-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
637 Li C, Wu X, Zhang H, Yang G, Hao M, Sheng S, Sun Y, Long J, Hu C, Sun X, Li L, Zheng J. A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis. Tumour Biol 2015;36:1739-45. [PMID: 25374064 DOI: 10.1007/s13277-014-2775-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
638 Ho CH, Tsai HW, Lee CY, Huang LJ, Chien RN, Wu IC, Chiu YC, Liu WC, Cheng PN, Chang TT, Chen SH. Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG. Sci Rep 2017;7:1957. [PMID: 28512353 DOI: 10.1038/s41598-017-02158-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
639 Imai N, Kinoshita A, Onoda H, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Tajiri H. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol 2013;15:575-81. [PMID: 23263911 DOI: 10.1007/s12094-012-0976-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
640 Wang B, Li F, Cheng L, Zhan Y, Wu B, Chen P, Shen J, Wu W, Ma X, Zhu J, Pan B, Guo W, Cheng Y. The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma. Future Oncology 2019;15:827-39. [DOI: 10.2217/fon-2018-0591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
641 Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311-318. [PMID: 23615394 DOI: 10.1159/000348325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 10.1] [Reference Citation Analysis]
642 Wang W, Huang S, Yuan J, Xu X, Li H, Lv Z, Yu W, Duan S, Hu Y. Reverse Multidrug Resistance in Human HepG2/ADR by Anti-miR-21 Combined with Hyperthermia Mediated by Functionalized Gold Nanocages. Mol Pharmaceutics 2018;15:3767-76. [DOI: 10.1021/acs.molpharmaceut.8b00046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
643 Nakagawa H, Shibata T. Comprehensive genome sequencing of the liver cancer genome. Cancer Lett 2013;340:234-40. [PMID: 23142287 DOI: 10.1016/j.canlet.2012.10.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
644 Bridges JF, Joy SM, Gallego G, Blauvelt BM, Geschwind JH, Pawlik TM. Priorities for Hepatocellular Carcinoma (HCC) Control: A Comparison of Policy Needs in Five European Countries. Journal of Comparative Policy Analysis: Research and Practice 2012;14:352-68. [DOI: 10.1080/13876988.2012.698581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
645 Liao M, Zhu Z, Wang H, Huang J. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol. 2017;52:624-634. [PMID: 28276833 DOI: 10.1080/00365521.2017.1292365] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
646 Shao Y, Zhang D, Li X, Yang J, Chen L, Ning Z, Xu Y, Deng G, Tao M, Zhu Y, Jiang J. MicroRNA-203 Increases Cell Radiosensitivity via Directly Targeting Bmi-1 in Hepatocellular Carcinoma. Mol Pharm 2018;15:3205-15. [PMID: 29906128 DOI: 10.1021/acs.molpharmaceut.8b00302] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
647 Jiang Q, Sun Y, Guo Z, Chen R, Ma S, Fu M, Zhu H, Ning Q, Lei P, Shen G. IL-23 enhances the malignant properties of hepatoma cells by attenuation of HNF4α. Oncotarget 2018;9:28309-21. [PMID: 29983862 DOI: 10.18632/oncotarget.24875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
648 Poojari R, Sawant AV, Kini S, Srivastava R, Panda D. Antihepatoma activity of multifunctional polymeric nanoparticles via inhibition of microtubules and tyrosine kinases. Nanomedicine (Lond) 2020;15:381-96. [PMID: 31990235 DOI: 10.2217/nnm-2019-0349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
649 Hay DC. Rapid and scalable human stem cell differentiation: now in 3D. Stem Cells Dev 2013;22:2691-2. [PMID: 23879796 DOI: 10.1089/scd.2013.1500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
650 Jin X, Tian S, Li P. Histone Acetyltransferase 1 Promotes Cell Proliferation and Induces Cisplatin Resistance in Hepatocellular Carcinoma. Oncol Res 2017;25:939-46. [PMID: 27938492 DOI: 10.3727/096504016X14809827856524] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
651 Sahin T, Serin A, Emek E, Bozkurt B, Arikan BT, Tokat Y. Effectiveness of Noninvasive Fibrosis Markers for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis. Transplantation Proceedings 2019;51:2397-402. [DOI: 10.1016/j.transproceed.2019.01.193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
652 Xiong J, Yang H, Luo W, Shan E, Liu J, Zhang F, Xi T, Yang J. The anti-metastatic effect of 8-MOP on hepatocellular carcinoma is potentiated by the down-regulation of bHLH transcription factor DEC1. Pharmacol Res 2016;105:121-33. [PMID: 26808085 DOI: 10.1016/j.phrs.2016.01.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
653 Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol. 2011;85:12881-12889. [PMID: 21976647 DOI: 10.1128/jvi.05633-11] [Cited by in Crossref: 114] [Cited by in F6Publishing: 83] [Article Influence: 10.4] [Reference Citation Analysis]
654 Iwahashi S, Ghaibeh AA, Shimada M, Morine Y, Imura S, Ikemoto T, Saito Y, Hirose J. Predictability of postoperative recurrence on hepatocellular carcinoma through data mining method. Mol Clin Oncol 2020;13:46. [PMID: 32874576 DOI: 10.3892/mco.2020.2116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
655 Jiang T, Xu JH, Zou Y, Chen R, Peng LR, Zhou ZD, Yang M. Diffusion-weighted imaging (DWI) of hepatocellular carcinomas: a retrospective analysis of the correlation between qualitative and quantitative DWI and tumour grade. Clin Radiol. 2017;72:465-472. [PMID: 28109531 DOI: 10.1016/j.crad.2016.12.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
656 Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ, Roberts LR, Heimbach JA, Leise MD. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clin Gastroenterol Hepatol. 2017;15:767-775.e3. [PMID: 28013117 DOI: 10.1016/j.cgh.2016.11.034] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 11.5] [Reference Citation Analysis]
657 Zeng Z, Cao Z, Tang Y. Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data. Oncol Lett 2020;20:231. [PMID: 32968453 DOI: 10.3892/ol.2020.12094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
658 Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ, Zhang ZH, Yang MJ, Wang JH, Chen B, Zeng SC, Luo JJ, Liu LX, Yan ZP. Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus. Oncotarget 2017;8:12108-19. [PMID: 28076848 DOI: 10.18632/oncotarget.14520] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
659 Petruzziello A, Marigliano S, Loquercio G, Coppola N, Piccirillo M, Leongito M, Azzaro R, Izzo F, Botti G. Hepatitis C Virus (HCV) genotypes distribution among hepatocellular carcinoma patients in Southern Italy: a three year retrospective study. Infect Agents Cancer 2017;12. [DOI: 10.1186/s13027-017-0162-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
660 Kenney AD, Dowdle JA, Bozzacco L, McMichael TM, St Gelais C, Panfil AR, Sun Y, Schlesinger LS, Anderson MZ, Green PL, López CB, Rosenberg BR, Wu L, Yount JS. Human Genetic Determinants of Viral Diseases. Annu Rev Genet 2017;51:241-63. [PMID: 28853921 DOI: 10.1146/annurev-genet-120116-023425] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
661 Cheng K, Wang C, Chang Y, Hung T, Lai C, Kuo C, Huang H. Mulberry fruits extracts induce apoptosis and autophagy of liver cancer cell and prevent hepatocarcinogenesis in vivo. Journal of Food and Drug Analysis 2020;28:84-93. [DOI: 10.1016/j.jfda.2019.06.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
662 Cui X, Hu ZP, Li Z, Gao PJ, Zhu JY. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol 2015; 21(28): 8588-8604 [PMID: 26229401 DOI: 10.3748/wjg.v21.i28.8588] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
663 Moreira JP, Malta Fde M, Diniz MA, Kikuchi L, Chagas AL, Lima Lde S, Gomes-Gouvêa MS, de Castro VF, Santana RA, Sumita NM, Paranagua Vezozzo DC, Carrilho FJ, Pinho JR. Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. Virology 2016;493:136-41. [PMID: 27035616 DOI: 10.1016/j.virol.2016.03.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
664 Ishii M, Mizuguchi T, Kawamoto M, Meguro M, Ota S, Nishidate T, Okita K, Kimura Y, Hui TT, Hirata K. Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3335-3342 [PMID: 24696614 DOI: 10.3748/wjg.v20.i12.3335] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
665 Lu T, Hao J, Shen C, Gu G, Zhang J, Xu N. Partial Hepatectomy-Induced Upregulation of miR-1907 Accelerates Liver Regeneration by Activation Autophagy. Biomed Res Int 2018;2018:3817057. [PMID: 30151380 DOI: 10.1155/2018/3817057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
666 Miki D, Ochi H, Hayes CN, Aikata H, Chayama K. Hepatocellular carcinoma: towards personalized medicine. Cancer Sci. 2012;103:846-850. [PMID: 22339805 DOI: 10.1111/j.1349-7006.2012.02242.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
667 Huang KW, Lai YT, Chern GJ, Huang SF, Tsai CL, Sung YC, Chiang CC, Hwang PB, Ho TL, Huang RL, Shiue TY, Chen Y, Wang SK. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma. Biomacromolecules. 2018;19:2330-2339. [PMID: 29808997 DOI: 10.1021/acs.biomac.8b00358] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
668 Yang JC. Value of matrix metalloproteinase-9 and secreted protein acidic and rich in cysteine in evaluation of severity and prognosis of primary liver cancer. Shijie Huaren Xiaohua Zazhi 2018; 26(17): 1036-1043 [DOI: 10.11569/wcjd.v26.i17.1036] [Reference Citation Analysis]
669 Xu Y, Zheng Y, Liu H, Li T. Modulation of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of hepatocellular carcinoma cells via MAPK signaling transduction. Int J Oncol. 2017;51:791-800. [PMID: 28677801 DOI: 10.3892/ijo.2017.4066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
670 Kong W, Gao M, Jin Y, Huang W, Huang Z, Xie Z. Prognostic model of patients with liver cancer based on tumor stem cell content and immune process. Aging (Albany NY) 2020;12:16555-78. [PMID: 32852285 DOI: 10.18632/aging.103832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
671 Gu Q, Zhang B, Sun H, Xu Q, Tan Y, Wang G, Luo Q, Xu W, Yang S, Li J, Fu J, Chen L, Yuan S, Liang G, Ji Q, Chen SH, Chan CC, Zhou W, Xu X, Wang H, Fang DD. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget 2015;6:20160-76. [PMID: 26062443 DOI: 10.18632/oncotarget.3969] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
672 Hwang IC, Chang J, Kim K, Park SM. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Sci Rep 2018;8:4968. [PMID: 29563592 DOI: 10.1038/s41598-018-23343-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
673 Abu-amara M, Cerocchi O, Malhi G, Sharma S, Yim C, Shah H, Wong DK, Janssen HLA, Feld JJ. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. Gut 2016;65:1347-58. [DOI: 10.1136/gutjnl-2014-309099] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
674 Liu H, Zhang Z, Chi X, Zhao Z, Huang D, Jin J, Gao J. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. Sci Rep 2016;6:31009. [PMID: 27484730 DOI: 10.1038/srep31009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
675 Bihari C, Rastogi A, Bhadoria AS, Saxena P, Sarin SK. Platelets contribute in hepatocellular carcinoma metastasis? Clinics and Research in Hepatology and Gastroenterology 2014;38:e111-2. [DOI: 10.1016/j.clinre.2014.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
676 Liang YJ, Yu H, Feng G, Zhuang L, Xi W, Ma M, Chen J, Gu N, Zhang Y. High-Performance Poly(lactic-co-glycolic acid)-Magnetic Microspheres Prepared by Rotating Membrane Emulsification for Transcatheter Arterial Embolization and Magnetic Ablation in VX2 Liver Tumors. ACS Appl Mater Interfaces 2017;9:43478-89. [PMID: 29116741 DOI: 10.1021/acsami.7b14330] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
677 Buendia MA, Bourre L, Cairo S. Myc target miRs and liver cancer: small molecules to get Myc sick. Gastroenterology. 2012;142:214-218. [PMID: 22178210 DOI: 10.1053/j.gastro.2011.12.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
678 Sarathi A, Palaniappan A. Novel significant stage-specific differentially expressed genes in hepatocellular carcinoma. BMC Cancer 2019;19:663. [PMID: 31277598 DOI: 10.1186/s12885-019-5838-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
679 Hieu NT, Sarnecki M, Tolboom J. The Safety and Immunogenicity of Two Hepatitis B Vaccine Formulations (Thiomersal-free and Thiomersal-containing) in Healthy Vietnamese Infants: A Phase III, Prospective, Single-blinded, Randomized, Controlled Trial. Pediatric Infectious Disease Journal 2015;34:79-83. [DOI: 10.1097/inf.0000000000000479] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
680 Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol. 2016;22:160-167. [PMID: 27044767 DOI: 10.3350/cmh.2016.22.1.160] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
681 Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y, Chayama K. Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection. J Viral Hepat. 2012;19:e126-e133. [PMID: 22239510 DOI: 10.1111/j.1365-2893.2011.01516.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
682 Xu Q, Liu X, Zheng X, Yao Y, Wang M, Liu Q. The transcriptional activity of Gli1 is negatively regulated by AMPK through Hedgehog partial agonism in hepatocellular carcinoma. Int J Mol Med 2014;34:733-41. [PMID: 25017332 DOI: 10.3892/ijmm.2014.1847] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
683 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
684 Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019;28:531-538. [PMID: 30464023 DOI: 10.1158/1055-9965.epi-18-0281] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
685 Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PL